[go: up one dir, main page]

US20070203175A1 - Productioin of dolasetron - Google Patents

Productioin of dolasetron Download PDF

Info

Publication number
US20070203175A1
US20070203175A1 US11/650,355 US65035507A US2007203175A1 US 20070203175 A1 US20070203175 A1 US 20070203175A1 US 65035507 A US65035507 A US 65035507A US 2007203175 A1 US2007203175 A1 US 2007203175A1
Authority
US
United States
Prior art keywords
acid
formula
canceled
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/650,355
Inventor
Janos Hajko
Tivadar Tamas
Adrienne Kovacsne-Mezei
Erika Molnarne
Csaba Peto
Csaba Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceuticals USA Inc
Priority to US11/650,355 priority Critical patent/US20070203175A1/en
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF RIGHTS IN BARBADOS Assignors: TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG
Assigned to TEVA, GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG reassignment TEVA, GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SZABO, CSADA, PETO, CSABA, HAJKO, JANOS, KOVACSNE-MEZEI, ADRIENNE, MOLNARNE, ERIKA MAGYAR, TAMAS, TIVADAR
Publication of US20070203175A1 publication Critical patent/US20070203175A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Definitions

  • the present invention relates to an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate, and intermediates thereof.
  • DLS-MsOH-H 2 O developed by Merrell Dow Pharmaceuticals is marketed as tablets for oral administration and as sterile solution for intravenous administration by Aventis, under the name Anzemet®.
  • DLS-MsOH and its monohydrate form can be prepared by a multi step synthesis, as described in EP patent No. 0339669 (“the EP '669 patent”) as illustrated in the following scheme
  • step (c) of the reaction involves oxidation with a molar equivalent of an expensive oxidizing reagent, 3-chloroperbenzoic acid (referred to as mCPBA), which transforms to 3-chlorobenzoic acid (referred to as mCBA), waste that is disposed at the end of the reaction.
  • mCPBA 3-chloroperbenzoic acid
  • mCBA 3-chlorobenzoic acid
  • waste waste that is disposed at the end of the reaction.
  • mCBA 3-chloroperbenzoic acid
  • CCA-epoxide is also contaminated by other aromatic impurities, such as [(3-ClPh)C(O)O] 2 (the corresponding peroxide ) in an amount of 5%. Therefore, the oxidation reaction as described above is non-economic for scale-up.
  • steps (e) and (f) are done by using periodic acid in ethyl acetate in step (e), and water as a solvent in step (f). Since, the reagents and the reduction products have low solubility in ethylacetate; the reaction disclosed in the above patent is slower. Also, the reaction in ethylacetate is more dangerous. In addition, since two different solvents are used in steps (e) and (f), a work-up procedure, which can lead to a decomposition of the sensitive 3-methoxycarbonyl-1,5-glutardialdehyde (the product of the oxidation step), is required.
  • the present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (referred to as an OAN compound salt) of formula Vs; wherein R 1 and R 2 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • OAN compound salt 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound
  • the present invention provides crystalline methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one (referred to as OAN-MsOH).
  • the present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound (referred to as a HAN compound salt) of formula VIs; wherein R 1 , R 2 and Z are described before.
  • a HAN compound salt 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound
  • the present invention provides crystalline methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol (referred to as HAN-MsOH).
  • the present invention provides a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (referred to as a SAN compound) of formula X; wherein R 1 and R 2 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • a SAN compound 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound
  • the present invention provides an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-4-alkoxycarbonyl-8-trialkylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) compound (referred to as a SQO compound) of formula XII wherein R is a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • the present invention provides crystalline endo-9-methoxycarbonyl-5-tert-butyldimethylsilyloxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-4-methoxycarbonyl-8-tert-butyldimethylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as SQO).
  • the present invention provides a quaternary ammonium salt of endo-5-hydroxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as a HQO-salt) of formula IIs; wherein Y is an acid selected from the group consisting of hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, triflu
  • the present invention provides a process for the preparation of a CCA-epoxide of formula IV comprising combining a CCA-ester of formula III, an oxidizing agent selected from a group consisting of hydroperoxide, dialkyl peroxide, peroxyacid, peroxyester, diacyl peroxide, persulphate, perborate, and perphosphate, a catalyst, and a solvent selected from the group consisting of water, a water miscible organic solvent, and mixtures thereof, to obtain a CCA-epoxide of formula IV; wherein, R 1 is C 1-6 alkyl or C 6-8 aryl, preferably, C 1-4 alkyl, more preferably, methyl.
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a CCA-epoxide of formula IV by the process of the invention; and converting it to a DLS-salt of formula VIIIs, wherein X is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenes
  • the present invention provides a process for the preparation of an OAN compound of formula V comprising combining a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, a water miscible organic solvent, and mixtures thereof, to form a reaction mixture; raising the pH of the reaction mixture; and adding to the resulting product a pH 4 buffer, a glycine C 1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3-acetonedicarboxylic acids, acetone and C 1-4 esters thereof, to form an OAN compound of formula V, wherein R 1 and R 2 are independently, C 1-6 alkyl or C 6-8 aryl, preferably, C 1-4 alkyl, more preferably, methyl.
  • the present invention provides a process for the 10 preparation of a DLS-salt of formula VIIIs, comprising preparing an OAN compound of formula V by the process of the invention; and converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for the preparation of an OAN compound salt of formula Vs comprising combining an OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof to form an OAN salt; wherein R 1 and R 2 are independently, C 1-6 alkyl or C 6-8 aryl, preferably, C 1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched
  • the present invention provides a process for purifying an OAN compound of formula V comprising combining an OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof; and adding a base to obtain a purified OAN compound.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing an OAN compound salt of formula Vs by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for the preparation of a HAN compound of formula VI comprising combining an OAN compound salt of formula Vs, a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, forming a HAN compound of formula VI.
  • the present invention provides a process for the preparation of a HAN compound salt of formula VIs comprising combining a HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide and mixtures thereof, forming a HAN salt, wherein, Z is an acid, preferably methanesulfonic acid, R 1 and R 2 are independently, C 1-6 alkyl or C 6-8 aryl, preferably, C 1-4 alkyl, more preferably, methyl.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear,
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing a HAN compound of formula VI by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for purifying a HAN compound of formula VI comprising combining a HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof; and adding a base to obtain a purified HAN compound.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone, a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroal
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing a HAN compound salt of formula VIs by the process of the invention, and converting it to a DLS-salt of form.
  • the present invention provides a process for the preparation of a SAN compound of formula X comprising combining a HAN-salt of formula VIs a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to obtain the SAN compound of formula X, wherein R 1 and R 2 are independently, C 1-6 alkyl or C 6-8 aryl, preferably, C 1-4 alkyl, more preferably methyl, R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, or together are a tert-butyldialkyl, preferably tert-butyldimethyl, and Z is an acid, preferably methanesulfonic acid.
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a SAN compound of formula X by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention also provides a process for the preparation a SQO compound of formula XII comprising mixing a SAN compound of formula X, a metal alkoxide, and a polar aprotic organic solvent to form a mixture; heating the mixture; and reacting it with a weak acid forming the SQO compound of formula XII, wherein, R is a C 1-6 alkyl or C 6-8 aryl, preferably a C 1-4 alkyl, more preferably methyl, and R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a SQO compound of formula XII by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention also provides a process for preparing HQO of formula II comprising mixing a SQO compound of formula XII, water and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids to obtain HQO of formula II.
  • an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-
  • the present invention further provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing HQO of formula II by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention provides another process for the preparation of a HQO-salt of formula IIs comprising combining HQO, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acids, forming
  • the present invention provides a process for purifying HQO of formula II comprising a) combining HQO of formula II, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acids; and b
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a HQO-salt of formula IIs by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising the steps of a) combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form a first intermediate mixture; b) adding to the first intermediate mixture an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent, to form a second intermediate mixture; c) raising the pH of the second intermediate mixture; d) reacting the products in the second reaction mixture with a pH 4 buffer, a glycine C 1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting
  • FIG. 1 illustrates powder X-ray diffraction pattern for OAN-MsOH.
  • FIG. 2 illustrates powder X-ray diffraction pattern for HAN-MsOH.
  • FIG. 3 illustrates powder X-ray diffraction pattern for SQO.
  • FIG. 4 illustrates powder X-ray diffraction pattern for HQO-HCl.
  • FIG. 5 illustrates powder X-ray diffraction pattern for HQO-CSA.
  • FIG. 6 illustrates powder X-ray diffraction pattern for HQO-base.
  • the present invention offers novel intermediates in the syntheses of Dolasetron salts, and processes for preparing them.
  • the invention also offers the use of these intermediates in novel processes for preparing Dolasetron salts, especially, the mesylate salt.
  • the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising the steps of a) combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form CCA-epoxide of formula IV; b) admixing CCA-epoxide with an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent; c) raising the pH of the mixture; d) admixing the mixture with a pH 4 buffer, a glycine C 1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3 acetone
  • the weak acid in step i) is selected from the group consisting of acetic acid, formic acid, acetic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, and salicylic acid.
  • the acid in step j) is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids.
  • the acid in step l) is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, preferably, methane sulfonic acid.
  • the present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (referred to as an OAN-salt) of formula Vs; wherein R 1 and R 2 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • OAN-salt 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound
  • said compound of formula Vs refers to the methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one (referred to as OAN-MsOH) of the following formula.
  • the present invention further provides crystalline OAN-MsOH.
  • the crystalline OAN-MsOH of the present invention may be characterized by a powder XRD diffraction pattern having peaks at about 8.5, 18.0, and 20.9 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • Crystalline OAN-MsOH may be further characterized by a powder XRD diffraction pattern having peaks at about 14.7, 22.7, 24.3, 25.0, 26.3 and 27.9 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • Crystalline OAN-MsOH may be also substantially identified by the PXRD pattern as depicted in FIG. 1 .
  • the present invention also provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound (referred to as a HAN-salt) of formula VIs; wherein R 1 , R 2 and Z are described before.
  • a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound referred to as a HAN-salt
  • said compound of formula VIs refers to the methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol (referred to as HAN-25 MsOH) of the following formula.
  • the present invention provides crystalline HAN-MsOH.
  • the crystalline HAN-MsOH of the present invention may be characterized by a powder XRD diffraction pattern having peaks at about 7.3, 11.6, and 14.6 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • the crystalline HAN-MsOH may be further characterized by a powder XRD diffraction pattern having peaks at about 15.9, 17.9, 19.0, 20.4, 21.9, 29.0 and 29.4 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • the crystalline HAN-MsOH may be also substantially identified by the PXRD pattern as depicted in FIG. 2 .
  • the present invention further provides a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (referred to as a SAN compound) of formula X; wherein R 1 and R 2 are described before.
  • a SAN compound 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound
  • said compound of formula X refers to 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-3-tert-butyldimethylsilyloxy-9-azabicyclo[3.3.1]nonane (referred to as SAN) of the following formula.
  • the present invention also provides an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-4-alkoxycarbonyl-8-trialkylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) compound (referred to as a SQO compound) of formula XII wherein R is a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, tert-butyldialkyl, more preferably, tert-butyldimethyl.
  • said compound of formula XII refers to endo-9-methoxycarbonyl-5-tert-butyldimethylsilyloxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-4-methoxycarbonyl-8-tert-butyldimethylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as SQO) of the following formula.
  • the present invention provides crystalline SQO.
  • the crystalline SQO of the present invention may be characterized by an XRD diffraction pattern having peaks at about 5.1, 10.1, 12.7, and 20.3 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • the crystalline SQO may be further characterized by an XRD diffraction pattern having peaks at about 15.2, 17.0, 17.6, 18.3, 19.1, and 19.8 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • the crystalline SQO may be also substantially identified by the PXRD pattern as depicted in FIG. 3 .
  • the present invention further provides a quaternary ammonium salt of endo-5-hydroxy-8-azatricyclo[5.3.1.0 3,8 ]undecan-10-one (trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as a HQO-salt) of formula IIs; wherein Y is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesul
  • said HQO-salt of formula IIs corresponds to HQO-HCl of the following formula.
  • the present invention provides crystalline HQO-HCl salt.
  • the crystalline HQO-HCl salt of the present invention may be characterized by a powder XRD diffraction pattern as depicted in FIG. 4 .
  • the present invention also provides a process for the preparation of a CCA-epoxide of formula IV comprising combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a diacyl peroxide, a persulphate, a perborate, a perphosphate, and a dimethyldioxiran, a catalyst, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to obtain the CCA-epoxide of formula IV, wherein R 1 is a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl.
  • an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a di
  • the CCA-ester of formula III is combined with a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to obtain a solution.
  • a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof.
  • the water miscible organic solvent is selected from the group consisting of linear or branched C 1-4 alcohols.
  • the C 1-4 alcohol is a C 1-3 alcohol, more preferably, a C 1-2 alcohol, most preferably, methanol.
  • a mixture of water and a water immiscible organic solvent may be used in the presence of a phase transfer catalyst.
  • the water immiscible organic solvent is selected from the group consisting of a C 1-8 halogenated hydrocarbon, a C 2-8 ester, a C 2-8 ether and a C 3-6 ketone.
  • a preferred C 1-8 halogenated hydrocarbon is a C 1-4 halogenated hydrocarbon, more preferably a C 1-2 halogenated hydrocarbon.
  • the C 1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform, more preferably dichloromethane.
  • a preferred C 2-8 ester is a C 2-6 ester, more preferably, a C 4-6 ester.
  • the C 4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate, more preferably ethyl acetate.
  • a preferred C 2-8 ether is a C 2-6 ether, more preferably, a C 4-6 ether.
  • the C 4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether, more preferably tert-butyl methyl ether.
  • a preferred C 3-6 ketone is a C 4-6 ketone.
  • the C 4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone, more preferably 2-pentanone.
  • the most preferred solvent is dichloromethane.
  • the phase transfer catalyst is preferably a quaternary ammonium salt, more preferably the phase transfer catalyst is tetrabutyl ammonium bromide.
  • the solution is combined with an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a diacyl peroxide, a persulphate, a perborate, a perphosphate, and a dimethyldioxiran, and a catalyst, to obtain a mixture.
  • an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a diacyl peroxide, a persulphate, a perborate, a perphosphate, and a dimethyldioxiran, and a catalyst, to obtain a mixture.
  • the hydroperoxide is RO—OH, wherein R is either H or an alkyl group.
  • the alkyl group is a C 1-6 alkyl, more preferably t-butyl.
  • a preferred dialkyl peroxide is RO—OR, wherein R is a C 1-6 alkyl, preferably t-butyl.
  • the peroxyacid is RCO—O—OH. More preferably, the RCO—O—OH is selected from the group consisting of: peracetic acid, trifluoroperacetic acid, perlauric acid, perbenzoic acid, and 3,5-dinitroperbenzoic acid.
  • the peroxyester is RCO—O—OR′, wherein R is phenyl or methyl, and R′ is an C 1-6 alkyl, preferably t-butyl.
  • a preferred diacyl peroxide is RCO—O—O—COR, wherein R is phenyl or methyl.
  • the more preferred oxidizing agent is hydroperoxide, most preferably, hydrogen peroxide.
  • hydroperoxide most preferably, hydrogen peroxide.
  • an aqueous solution of hydrogen peroxide is used.
  • a preferred concentration of the solution is of about 3% to about 50%, more preferably of about 20% to about 40%, most preferably of about 30% to about 35%.
  • the catalyst is selected from the group consisting of Zeolites and polyoxometalates.
  • the metal moiety of the polyoxometalates is selected from the group consisting of tungsten, molybdenum, rhenium, vanadium and niobium. More preferably, the catalyst is either sodium tungstate dihydrate or sodium molybdenate dihydrate.
  • a preferred amount of the catalyst is about 0.01 mole % to about 50 mole % per mole of the CCA-ester, more preferably about 1 mole % to about 10 mole % per mole of the CCA-ester, most preferably about 2 mole % per mole of the CCA-ester.
  • the reaction mixture is maintained at a temperature of about 0° C. to about 80° C., preferably about 30° C. to about 80° C., more preferably, at a temperature of about 15° C. to about 65° C., most preferably at a temperature of about 60° C. to about 65° C.
  • the reaction mixture is preferably, maintained at such temperature for a period of about 0.5 hours to about 24 hours, more preferably for about 1 to about 10 hours, most preferably for about 2 hours to about 4 hours.
  • the progress of the reaction may be monitored by gas-chromatography (referred to as GC) or by thin-layer chromatography (referred to as TLC).
  • GC gas-chromatography
  • TLC thin-layer chromatography
  • an eluent of n-hexane and ethylacetate in a ratio of 1:1 may be used.
  • the process for preparing a CCA-ester of formula IV may further comprise a recovery step.
  • the CCA-epoxide of formula IV may be recovered comprising the steps of adjusting the temperature of the reaction mixture to a temperature of about 20° C. to about 30° C.; extracting the product with a water immiscible organic solvent, preferably, dichloromethane; and evaporating the solvent.
  • the process for preparing a CCA-ester of formula IV may further comprise a process for converting it to a DLS-salt of formula VIIIs, wherein, X is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthal
  • DLS-salt of formula VIIIs corresponds to DLS-MsOH of the following formula.
  • the process of the present invention provides an OAN compound of formula V prepared by a process comprising an oxidation reaction followed by Robinson-Schöpf reaction, wherein both reactions are done in water, and therefore can be done concurrently, i.e., without isolation of the oxidation product, prior to the Robinson-Schöpf reaction.
  • the oxidation applies the use of periodic acid in water, in which the reagents and the reduction products have high solubility; hence, the reaction is fast. Also, using water allows controlling the exothermic nature of the reaction, thus, reducing the danger.
  • the present invention further provides a process for the preparation of an OAN compound of formula V comprising combining a) a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to form a reaction mixture; b) raising the pH of the reaction mixture; c) and adding to the reaction mixture of step b) a pH 4 buffer, glycine C 1-4 ester or salts thereof, and a substance comprising carbonyl moiety selected from the group consisting of 1,3-acetonedicarboxylic acid, acetone and a C 1-4 ester thereof, to form the OAN compound of formula V, wherein R 1 and R 2 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl.
  • OAN compound of formula V corresponds to OAN of the following formula.
  • Combining a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to form a reaction mixture; and raising the pH of the reaction mixture, may be designated as an oxidation reaction.
  • a CCA-epoxide of formula IV with an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvent and mixtures thereof provides a first reaction mixture.
  • the water miscible organic solvent is selected from the group consisting of: a nitrile, a ketone and an ether.
  • a preferred nitrile is a C 2-4 nitrile.
  • the C 2-4 nitrile is acetonitrile, propionitrile or butyronitrile.
  • a preferred ketone is a C 3-6 ketone.
  • the C 3-6 ketone is acetone, methyl ethyl ketone or diethyl ketone.
  • the ether is a cyclic ether.
  • a preferred cyclic ether is THF, 1,4-dioxane or 1,3-dioxolane.
  • the preferred solvent is water.
  • the oxidizing agent is selected from the group consisting of: periodic acid and salts thereof, lead tetraacetate, cerium and ammonium nitrate (Ce(NH 4 ) 2 (NO 3 ) 6 ). More preferably, the oxidizing agent is periodic acid. Preferably, the oxidizing agent is added in the form of a solution when the solvent is water.
  • the first reaction mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably at a temperature of about 10° C. to about 15° C.
  • the first mixture is maintained for a period of about 0.5 hours to about 24 hours, and more preferably for about 1 to about 3 hours. Maintaining the first reaction mixture is preferably done while stirring.
  • the first reaction mixture is, preferably, acidic.
  • the pH of the acidic first reaction mixture is of about 0.5 to about 7, more preferably of about 0.5 to about 2.
  • the pH of the maintained first reaction mixture is increased to about 2 to about 7.
  • the pH is raised, preferably to about 3.5 to about 4.5.
  • the pH is raised by using a water immiscible base, more preferably either poly(4-vinylpyridine) or OH resins, and even more preferably, OH resins.
  • the water immiscible base is, preferably, filtered off, more preferably through Celite, providing an aqueous solution of the product of the oxidation reaction.
  • adjusting the pH is performed at a temperature of about 15° C. to about 35° C., more preferably at about room temperature.
  • the reaction may be run stepwise or concurrently, i.e., without isolation of the oxidation product prior to the Robinson-Schöpf reaction.
  • the process is run concurrently.
  • a pH 4 buffer, a glycine C 1-4 ester or salts thereof, and a substance comprising carbonyl moiety selected from the group consisting of a 1,3-acetonedicarboxylic acids, acetone and C 1-4 esters thereof are added to obtain a second reaction mixture.
  • the pH 4 buffer is an amine-free buffer.
  • the amine-free buffer is selected from the group consisting of: a citric acid-sodium hydroxide-hydrochloric acid buffer, a citric acid-disodium hydrogenphosphate buffer, a sodium acetate-acetic acid buffer, a potassium diphthalate-sodium hydroxide buffer, sodium dihydrogen phosphate and potassium hydrogen phthalate. More preferably, the amine-free buffer is potassium hydrogen phthalate.
  • the buffer is used in an amount of about 1 to about 10 mole equivalents, more preferably about 2 to 5 mole equivalents, most preferably about 3 mole equivalents, per mole equivalent of the CCA-epoxide.
  • the glycine C 1-4 ester is a methyl ester.
  • a preferred salt of the glycine C 1-4 ester is glycine hydrochloride. More preferably, the glycine C 1-4 ester or salts thereof, is glycin methylester hydrochloride.
  • the C 1-4 ester of 1,3-acetonedicarboxylic acid is selected from the group consisting of symmetrical and mixed C 1-4 ester derivatives.
  • the preferred substance comprising a carbonyl moiety is 1,3-acetonedicarboxylic acid.
  • the second reaction mixture is maintained at a temperature of about 0° C. to about 60° C., more preferably, at about 10° C. to about 40° C., most preferably at about room temperature.
  • the second mixture is maintained, preferably for about 10 to about 72 hours, and more preferably for about 12 to about 24 hours, most preferably for about 18 hours. Maintaining the second reaction mixture is preferably done while stirring.
  • the process for preparing the OAN compound of formula V may further comprise a recovery step.
  • the recovery may be done by any known process.
  • the OAN compound of formula V may be recovered by filtering off the undissolved solid particles from the second reaction mixture, preferably, through Celite, followed by washing with water, and combining the filtrate with an inorganic base to obtain a pH of about 7 to about 9, more preferably, of about 7.5 to about 8.
  • the inorganic base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate, more preferably is sodium bicarbonate.
  • the basic filtrate is then extracted with a water immiscible organic solvent, preferably a C 2-5 acetate, more preferably isobutylacetate, and the solvent is evaporated.
  • the present invention also provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing the OAN compound of formula V by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • This conversion to a DLS salt of formula VIIIs may be carried out by the process of the invention or any other known process converting an OAN compound of formula V to a DLS salt of formula VIIIs as described for example in EP 0339699, examples 4 and 9.
  • the present invention provides a process for the preparation of an OAN-salt of formula Vs comprising reacting the OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide and mixtures thereof, wherein, R 1 and R 2 are described before, and Z is an acid, preferably, methanesulfonic acid.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1
  • the present invention further provides a process for purifying the OAN compound of formula V comprising reacting the OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide and mixtures thereof; and adding a base.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkyl
  • the OAN compound of formula V used as a starting material may be a crude OAN compound or a concentrated solution of a crude OAN compound, obtained in the recovery process of the OAN compound.
  • the OAN compound of formula V is dissolved in an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide and mixtures thereof, prior to adding the acid.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide and mixtures thereof
  • the C 1-4 alcohol is a C 1-3 alcohol.
  • the C 1-3 alcohol is methanol, n-propanol, isopropanol or ethanol.
  • a preferred C 2-8 ester is a C 2-6 ester, more preferably, a C 2-4 ester.
  • a preferred C 2-4 ester is ethyl acetate, propylacetate, n-butyl acetate, or isobutylacetate.
  • a preferred linear, branched or cyclic C 2-8 ether is a C 2-7 ether, more preferably, a C 2-5 ether.
  • a preferred C 2-5 ether is 1,4-dioxane, diisopropyl ether, t-butyl methyl ether or tetrahydrofuran.
  • the C 3-6 ketone is a C 3-5 ketone.
  • the C 3-5 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone, 3,3-dimethyl-2-butanone or acetone.
  • the C 5-8 aliphatic hydrocarbon is a C 5-7 aliphatic hydrocarbon, more preferably, a C 6-7 aliphatic hydrocarbon.
  • a preferred C 6-7 aliphatic hydrocarbon is either n-hexane, or n-heptane.
  • a preferred C 1-8 halogenated hydrocarbon is a C 1-6 halogenated hydrocarbon, more preferably a C 1-4 halogenated hydrocarbon, most preferably a C 1-2 halogenated hydrocarbon.
  • a preferred C 1-2 halogenated hydrocarbon is dichloroethane, chloroform or dichloromethane.
  • a preferred C 1-4 nitroalkane is a C 1-2 nitroalkane.
  • the C 1-2 nitroalkane is nitromethane or nitroethane.
  • the C 1-4 alkylcyanide is a C 1-3 alkylcyanide.
  • a preferred C 1-3 alkylcyanide is either propionitrile or acetonitrile.
  • a preferred C 6-8 aromatic hydrocarbon is a C 6-7 aromatic hydrocarbon.
  • the C 6-7 aromatic hydrocarbon is toluene.
  • a preferred C 3-10 amide is a C 3-6 amide.
  • the C 3-6 amide is dimethylformamide.
  • the more preferred solvent is a mixture of a C 2-4 ester and a C 1-3 alcohol, more preferably, of isobutylacetate and ethanol.
  • the mixture contains isobutylacetate and ethanol in a ratio of about 1:1, respectively.
  • the acid is either an organic acid or an inorganic acid.
  • the organic acid is selected from the group consisting of carboxylic acids and sulfonic acids.
  • the carboxylic acid is selected from the group consisting of: formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids. More preferably, the carboxylic acid is tartaric acid.
  • a preferred sulfonic acid is selected from the group consisting of: methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids. More preferably, the sulfonic acid is either methane sulfonic acid or camphorsulfonic acid.
  • the inorganic acid is selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and fluoroboric acid. The more preferred inorganic acid is hydrochloric acid. The more preferred acid is methane sulfonic acid.
  • the mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably, at a temperature of about 20° C. to about 50° C., most preferably at a temperature of about 30° C. to about 40° C.
  • the mixture is preferably maintained at such temperature for about 1 hour to about 24 hours, and more preferably, for about 2 to about 12 hours. Maintaining the reaction mixture is preferably done while stirring.
  • reacting the OAN compound with an acid provides the corresponding OAN-salt of formula Vs.
  • the OAN-salt of formula Vs precipitates from the reaction mixture.
  • the precipitate is reacted with a base providing the OAN compound of formula V back again.
  • the precipitate is recovered prior to reacting with a base.
  • the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. More preferably, the base is sodium bicarbonate.
  • the process for preparing an OAN-salt of formula Vs may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for the preparation of a HAN compound of formula VI comprising combining an OAN salt of formula Vs, a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof to obtain the HAN compound of formula VI.
  • the OAN-salt of formula Vs is OAN-MsOH.
  • the OAN-salt is used as a starting material, it is combined with a water miscible organic solvent, providing a suspension.
  • the suspension is prepared at a temperature of about 15° C. to about 35° C., preferably of about 20° C. to about 25° C.
  • the OAN compound of formula V may be used as a starting material.
  • the OAN compound of formula V is used as a starting material, it is combined with a water miscible organic solvent, providing a solution.
  • the water miscible organic solvent is a C 1-4 alcohol, more preferably, a C 1-3 alcohol, most preferably, a C 1-2 alcohol.
  • a preferred C 1-2 alcohol is methanol.
  • the reducing reagent is a metal hydride complex, preferably lithium borohydride, selectricde or sodium borohydride, more preferably, sodium borohydride.
  • the reducing agent may be used in a basic aqueous solution or as a solid.
  • a basic aqueous solution of the reducing agent may be used.
  • the basic aqueous solution is an aqueous solution of an alkali hydroxide, more preferably an aqueous solution of sodium hydroxide.
  • the basic aqueous solution contains about 30% to about 50% by weight, preferably about 30%, of sodium hydroxide.
  • the solution of the OAN compound of formula V in a C 1-4 alcohol and the basic aqueous solution of the reducing agent are combined at a temperature of about 0° C. to about 10° C., preferably about 0° C. to about 5° C.
  • the solution of the reducing reagent is added drop-wise to the solution of the OAN compound in a C 1-4 alcohol.
  • a solid reducing agent may be used.
  • the suspension of the OAN-salt of formula Vs in a C 1-4 alcohol and the reducing agent are combined at a temperature of about 15° C. to about 35° C., preferably about 20° C. to about 25° C.
  • the reducing reagent is added portion-wise to the suspension of the OAN-salt in a C 1-4 alcohol.
  • the portion-wise addition of the reducing agent is done while maintaining the temperature at about 15° C. to about 35° C., preferably about 25° C. to about 35° C.
  • the mixture is maintained for about a half hour to about 2 hours, preferably for about a half hour to about an hour at such temperature, prior to recovering the HAN compound of formula VI.
  • the mixture When the OAN compound of formula V is used as a starting material, the mixture is maintained at a temperature of about 0° C. to about 5° C., for about an hour, and when the starting material is OAN-salt of formula Vs, the mixture is maintained at a temperature of about 25° C. to about 35° C., for about a half an hour.
  • the reaction may be monitored by TLC using ethylacetate as an eluent.
  • the process for preparing the HAN compound of formula VI may further comprise a recovery step.
  • the recovery may be carried out by any known method.
  • the HAN compound of formula VI may be recovered by a process comprising adding an acid, preferably a water miscible organic acid, more preferably acetic acid, to the reaction mixture, to give a precipitate.
  • the precipitate is then combined with water and with a halogenated hydrocarbon, preferably a C 1-2 halogenated hydrocarbon, to give a solution, optionally followed by filtration.
  • the aqueous phase is then extracted, and the solvent is evaporated form the combined organic phase, providing a crude HAN compound.
  • the mixture is evaporated and the residue is combined with ethylacetate.
  • the undissolved particles are then, filtered off, and the filtrate is concentrated, providing a crude HAN compound.
  • the present invention further provides a process for the preparation of a HAN-salt of formula VIs, comprising reacting the HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof, wherein, Z, R 1 and R 2 are described before.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C
  • said HAN compound of formula VI corresponds to HAN of the following formula
  • said HAN-salt of formula VIs corresponds to HAN-MsOH of the following formula
  • the process for preparing the HAN compound of formula VI may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • the present invention also provides a process for purifying the HAN compound of formula VI comprising combining the HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof; and adding a base.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alky
  • the HAN compound of formula VI used as a starting material may be a crude HAN compound.
  • the HAN compound of formula VI is dissolved in an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, linear, branched or cyclic C 2-8 ethers, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof, prior to adding the acid.
  • an organic solvent selected from the group consisting of a C 1-4 alcohol, a C 2-8 ester, linear, branched or cyclic C 2-8 ethers, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, a C 1-8 halogenated hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkylcyanide, a C 6-8 aromatic hydrocarbon, a C 3-10 amide, and mixtures thereof
  • the C 1-4 alcohol is a C 1-3 alcohol.
  • the C 1-3 alcohol is methanol, ethanol, n-propanol, or isopropanol.
  • a preferred C 2-8 ester is a C 2-6 ester, more preferably a C 4-6 ester.
  • a preferred C 4-6 ester is ethyl acetate, propyl acetate, butyl acetate, or isobutyl acetate.
  • a preferred linear, branched or cyclic C 2-8 ether is a C 2-7 ether, more preferably a C 2-6 ether.
  • a preferred C 2-6 ether is tetrahydrofuran, 1,4-dioxane, diisopropyl ether, or t-butyl methyl ether.
  • the C 3-6 ketone is a C 3-5 ketone.
  • the C 3-5 ketone is acetone, methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone, or 3,3-dimethyl-2-butanone.
  • the C 5-8 aliphatic hydrocarbon is a C 5-7 aliphatic hydrocarbon, more preferably a C 6-7 aliphatic hydrocarbon.
  • a preferred C 6-7 aliphatic hydrocarbon is either n-hexane, or n-heptane.
  • a preferred C 1-8 halogenated hydrocarbon is a C 1-6 halogenated hydrocarbon, more preferably a C 1-4 halogenated hydrocarbon, most preferably a C 1-2 halogenated hydrocarbon.
  • a preferred C 1-2 halogenated hydrocarbon is dichloromethane, dichloroethane, or chloroform.
  • a preferred C 1-4 nitroalkane is a C 1-2 nitroalkane.
  • the C 1-2 nitroalkane is nitromethane or nitroethane.
  • the C 1-4 alkylcyanide is a C 1-3 alkylcyanide.
  • a preferred C 1-3 alkylcyanide is either acetonitrile or propionitrile.
  • a preferred C 6-8 aromatic hydrocarbon is a C 6-7 aromatic hydrocarbon.
  • the C 6-7 aromatic hydrocarbon is toluene.
  • a preferred C 3-10 amide is a C 3-6 amide.
  • the C 3-6 amide is dimethylformamide.
  • the more preferred solvent for dissolving the HAN compound of formula VI is a C 2-4 ester, most preferably, ethylacetate.
  • the acid is the same as the acid in the process for preparing the purified OAN compound of formula V.
  • the more preferred acid is methane sulfonic acid.
  • the mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably, at a temperature of about 20° C. to about 50° C., most preferably at a temperature of about 30° C. to about 40° C.
  • the mixture is preferably maintained at such temperature for about 0.5 hours to about 24 hours, and more preferably for about 1 hour to about 3 hours, most preferably for about 2 hours. Maintaining the reaction mixture is preferably done while stirring.
  • reacting the HAN compound with an acid provides a corresponding HAN-salt of formula VIs.
  • the HAN-salt of formula VIs precipitates from the reaction mixture.
  • the HAN-salt of formula VIs is reacted with a base, providing the HAN compound of formula VI back again.
  • the precipitate is recovered prior to reacting with a base.
  • the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. More preferably, the base is sodium bicarbonate.
  • the process for preparing a HAN-salt of formula VIs may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • the present invention further provides a process for the preparation of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]-nonane compound (referred to as a SAN compound) of formula X wherein R 1 and R 2 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, a C 1-4 alkyl, more preferably, methyl, and R 3 R 4 R 5 are independently a C 1-6 alkyl or a C 6-8 aryl, preferably, tert-butyldialkyl, more preferably, tert-butyldimethyl comprising combining a HAN compound of formula VI or a salt thereof a silylating agent selected from the group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (
  • the HAN-salt of formula VI is combined with an a-protic organic solvent.
  • the a-protic organic solvent is selected from a group consisting of a C 1-8 halogenated hydrocarbon, a C 2-8 ester, a C 2-8 ether, C 6-8 aromatic hydrocarbon, C 3-10 amide, and a C 3-6 ketone to obtain a suspension.
  • a preferred C 1-8 halogenated hydrocarbon is a C 1-5 halogenated hydrocarbon, more preferably, a C 1-3 halogenated hydrocarbon.
  • the a C 1-3 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform.
  • a preferred C 2-8 ester is a C 4-6 ester.
  • the C 4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate.
  • a preferred C 2-8 ether is a C 4-6 ether.
  • the C 4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether.
  • a preferred C 6-8 aromatic hydrocarbon is a C 6-7 aromatic hydrocarbon.
  • the C 6-7 aromatic hydrocarbon is toluene.
  • a preferred C 3-10 amide is a C 3-6 amide.
  • the C 3-6 amide is dimethylformamide.
  • a preferred C 3-6 ketone is a C 4-6 ketone.
  • the C 4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone.
  • the preferred solvent is dichloromethane.
  • the base is added to the suspension, providing a solution.
  • about 2 to about 10 mole equivalent of base per mole equivalent of the HAN-salt is used. More preferably, about 3 to about 6 mole equivalent of base per mole equivalent of the HAN-salt is used.
  • the base is selected from the group consisting of: sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate potassium bicarbonate, trialkyl amines, and N-containing heterocycles.
  • the trialkylamine is triethylamine, diisopropylethyl amine or tributyl amine.
  • a preferred N-containing heterocycle is piperidine, pyridine, pyrimidine, piperazine, triazine, pyrrolidine, imidazole, or triazole.
  • the preferred base is an N-containing heterocycle, more preferably, imidazole.
  • the base is added at a temperature of about 15° C. to about 55° C., more preferably, at 20° C. to about 25° C.
  • the silane is selected from the groups consisting of triethylsilane, triisopropylsilane, and triphenylsilane.
  • the silyl halogendie is selected from the group consisting of trimethylsily chloride, tert-butyldimethylsilyl chloride, and tert-butyldiphenylsilyl chloride.
  • the silyl cyanide is selected from the group consting of trimethylsilyl cyanide, triethylsilyl cyanide, and tert-butyldimethylsilyl cyanide.
  • the silyl amine is trimethylsilyldiethylamine or triethylsilyldiethylamine.
  • the silyl amide is selected from the group consisting of N-methyl-N-trimethylsilylacetamide, N-methyl-N-triethylsilylacetamide, and tert-butyldimethylsilyl-N-methyltrifluoroacetamide.
  • the silyl triflate is selected from the group consisting of trimethylsilyl trifluoromethanesulfonate, triethylsilyl trifluoromethanesulfonate, and tert-butyldimethylsilyl trifluoromethanesulfonate.
  • the silazane is hexamethyldisilazane or hexaethyldisilazane.
  • the silylating agent is trialkylsilyl halogenide.
  • the alkyl group is t-butyldimethyl.
  • the preferred silylating agent is tert-butyldimethylsilyl chloride.
  • the silylating agent is added to the solution, providing a reaction mixture.
  • the mixture is maintained at a temperature of about 0° C. to about 80° C., more preferably, more preferably at a temperature of about 20° C. to about 60° C., most preferably, at about 40° C. to about 60° C.
  • the mixture is maintained for about 0.5 hours to about 24 hours, and more preferably, for about 4 to about 12 hours.
  • the progress of the reaction may be monitored by HPLC or by TLC.
  • HPLC HPLC
  • TLC TLC
  • an eluent of ethyl acetate is used.
  • the process for preparing the SAN compound of formula X may further comprise a recovery step.
  • the SAN compound of formula X may be recovered by extracting the product with water, and evaporating the solvent.
  • the SAN compound of formula X may also be prepared from the HAN compound of formula VI using similar conditions as used when the HAN-salt of formula VIs is the starting material, however, a smaller amount of base and of a silylated agent may be used and the most preferred solvent is dichloromethane.
  • a smaller amount of base and of a silylated agent may be used and the most preferred solvent is dichloromethane.
  • the HAN compound of formula VI is the starting material, about 1 to about 5 mole equivalent of base per mole equivalent of the HAN compound is used, more preferably, about 1 to about 3 mole equivalent of base per mole equivalent of the HAN compound is used.
  • about 1 to about 3 mole equivalent of silylating agent per mole equivalent of the HAN compound is used. More preferably, about 1 to about 2 mole equivalent of silylating agent per mole equivalent of the HAN compound is used.
  • the process for preparing the SAN compound of formula X may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • the present invention provides a process for the preparation of a SQO compound of formula XII comprising mixing a SAN compound of formula X, a metal alkoxide, and a polar a-protic organic solvent to form a mixture; heating the mixture; and reacting this mixture with a weak acid, forming the SQO compound of formula XII, wherein, R, R 3 R 4 and R 5 are described before.
  • a preferred polar a-protic organic solvent is selected from the group consisting of a C 2-8 ether having a boiling point of about 60° C. to about 100° C.
  • the C 2-8 ether having a boiling point of about 60° C. to about 100° C. is tetrahydrofuran (referred to as THF), 2-methyltetrahydrofuran, tetrahydropyran, monoglyme, diisopropyl ether, or methyl t-butyl ether.
  • THF tetrahydrofuran
  • 2-methyltetrahydrofuran 2-methyltetrahydrofuran
  • tetrahydropyran monoglyme
  • diisopropyl ether or methyl t-butyl ether.
  • the more preferred polar aprotic organic solvent is THF.
  • the SAN compound of formula X is dissolved in a polar a-protic organic solvent, prior to adding the metal alkoxide.
  • the metal alkoxide is selected from the group consisting of lithium alcoholates, sodium alcoholates and potassium alcoholates; wherein the alcoholate moiety contains 1 to 4 carbons. More preferably, the metal alkoxide is potassium tert-butoxide.
  • the solution is heated to a temperature of about 40° C. to about 120° C., more preferably, to a temperature of about 60° C. to about 80° C.
  • the solution is heated, preferably, for about 0.5 hours to about 8 hours, and more preferably, for about 1 hour to about 3 hours. Heating the solution is preferably done under stirring.
  • the solution is concentrated, preferably, by distillation of the polar a-protic organic solvent, providing a mixture.
  • the mixture is, preferably, cooled to a temperature of about 0° C. to about 30° C., more preferably, to a temperature of about 15° C. to about 25° C., prior to reacting with the acid.
  • the weak acid is selected from the group consisting of acetic acid, formic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids.
  • acetic acid formic acid, propionic acid
  • maleic acid fumaric acid
  • succinic acid oxalic acid
  • tartaric acid citric acid
  • mandelic acid mandelic acid
  • benzoic acid salicylic acid
  • naphthalene carboxylic and dicarboxylic acids methanes
  • the acid is a water miscible organic acid, preferably acetic acid, more preferably acetic acid combined with water, providing a diluted aqueous solution of acetic acid.
  • the acid is added to the cooled mixture, providing an acidic mixture, prior to recovering the SQO compound of formula XII.
  • the pH of the acidic mixture is of about 4 to about 6, more preferably, of about 5 to about 6.
  • the process for preparing the SQO compound of formula XII may further comprise a step of recovering it.
  • the recovery may be carried out by any known method.
  • the SQO compound of formula XII may be recovered by a process comprising combining the acidic mixture with a base, providing a slight basic mixture; concentrating the slight basic mixture; precipitating the SQO compound of formula XII; and recovering it.
  • the pH of the slightly basic mixture is of about 7 to about 8.
  • the base is selected from a group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate.
  • the more preferred base is sodium bicarbonate.
  • the basic mixture is concentrated by removing the polar a-protic organic solvent.
  • removal of the polar a-protic organic solvent is done by distillation.
  • the removal of the polar a-protic organic solvent provides a concentrated aqueous mixture.
  • the precipitation of the SQO compound of formula XII is done by cooling the concentrated aqueous mixture to about 0° C. to about 10° C., preferably about 2° C. to about 8° C.
  • the cooled concentrated aqueous mixture is maintained, preferably, for about 3 hours to about 24 hours, and more preferably, for about 8 hours to about 18 hours, prior to filtering the precipitate.
  • the filtered SQO compound of formula XII is washed with water, and dried.
  • the process for preparing the SQO compound of formula XII may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • the present invention also provides a process for preparing HQO of formula II comprising mixing a SQO compound of formula XII, a solvent selected from the group consisting of water and a water-miscible organic solvent, and an acid to obtain HQO.
  • the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids.
  • the SQO compound of formula XII is combined with water or a water-miscible organic solvent to obtain a suspension.
  • the water-miscible organic solvent is dimethylformamide, dimethylacetamide, dimethyl sulfoxide, or diglyme, more preferably dimethylformamide.
  • the SQO compound of formula XII is combined with water at a temperature of about 10° C. to about 50° C., more preferably, at 20° C. to about 25° C.
  • the acid is added to the suspension providing a solution.
  • the addition of the acid provides an acidic solution.
  • the acidic solution has a pH of about 0.5 to about 3, more preferably, of about 1 to about 2.
  • the acidic solution is heated, preferably, to a temperature of about 80° C. to about 100° C.
  • the heated solution is maintained, preferably, for about 3 hours to about 24 hours, and more preferably, for about 6 hours to about 10 hours. Heating the solution is preferably done while stirring.
  • the progress of the reaction may be monitored by HPLC or by TLC.
  • HPLC HPLC
  • TLC TLC
  • an eluent of methylene chloride and methanol in a ratio of 1:1 is used.
  • the process for preparing HQO of formula II may further comprise a recovery step.
  • the recovery may be carried out by any known method.
  • HQO of formula II may be recovered by cooling the heated acidic solution, adding a base to the cooled acidic mixture, extracting the product with a water immiscible organic solvent, and evaporating the water immiscible organic solvent to obtain HQO of formula II.
  • the heated solution is cooled to a temperature of about 0° C. to about 30° C., more preferably, to a temperature of about 15° C. to about 25° C.
  • a base is added to the cooled solution.
  • the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate.
  • the more preferred base is sodium hydroxide.
  • the addition of the base provides a basic mixture.
  • the basic mixture has a pH of about 8 to about 13, more preferably, of about 11 to about 12.
  • the preferred water immiscible organic solvent is selected from the group consisting of a C 2-8 ester, a linear, branched or cyclic C 2-8 ether, a C 3-6 ketone and a C 5-8 aliphatic hydrocarbon, and a C 1-8 halogenated hydrocarbon.
  • the most preferred water immiscible organic solvent is methylene chloride.
  • a preferred C 2-8 ester is a C 4-6 ester.
  • the C 4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate.
  • a preferred C 2-8 ether is a C 4-6 ether.
  • the C 4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether.
  • a preferred C 3-6 ketone is a C 4-6 ketone.
  • the C 4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone.
  • a preferred C 5-8 aliphatic hydrocarbon is a C 6-7 aliphatic hydrocarbon.
  • the C 6-7 aliphatic hydrocarbon is n-hexane or n-heptane.
  • a preferred C 1-8 halogenated hydrocarbon is a C 1-2 halogenated hydrocarbon.
  • the C 1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform.
  • HQO of formula II may be prepared directly from the SAN compound of formula X, i.e., without isolating the SQO compound of formula XII.
  • the reaction may include the same steps as described in the process for preparing the SQO compound of formula XII, but using a strong acid instead of a weak acid, and heating.
  • the stron acid is selected from the group consisting of methanesulfonic acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, and triflic acid.
  • This process for preparing HQO of formula II from the SQO compound of formula XII or directly from the SAN compound of formula X may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • reacting SAN with an acid provides the corresponding salt of HQO, a HQO-salt of formula IIs.
  • the HQO-salt of formula IIs precipitates in the reaction mixture.
  • the HQO-salt of formula IIs is reacted with a base, providing HQO of formula II back again.
  • the precipitate is recovered prior to reacting with a base.
  • the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, and potassium bicarbonate, more preferably sodium bicarbonate.
  • the present invention also provides another process for the preparation of a HQO-salt of formula IIs comprising combining HQO, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acid to obtain a HQ
  • the present invention provides a process for purifying HQO of formula II by a process comprising combining HQO of formula II, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acid forming a mixture,
  • the alcohol is a C 1-4 alcohol, more preferably, ethanol.
  • the acid is an organic acid, more preferably, a sulfonic acid, most preferably, methanesulfonic acid.
  • the process for preparing a HQO-salt of formula IIs can further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • HQO-salt of formula IIs may be converted to a DLS-salt of formula VIIIs comprising converting it to the free base, HQO of formula II; reacting HQO with a base to form a reaction mixture; mixing the reaction mixture with an anhydride, indole-3-carboxylic acid, an organic solvent, and a catalyst to form a mixture; and reacting the mixture with an acid, to obtain the DLS-salt of formula VIIIs.
  • the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate.
  • the more preferred base is sodium bicarbonate.
  • the organic solvent is selected from the group consisting of a C 1-2 halogenated hydrocarbon, a C 6-8 aromatic hydrocarbon, a C 1-4 nitroalkane, a C 1-4 alkyl cyanide, trifluoroacetic acid and mixtures thereof.
  • a preferred C 1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform, more preferably dichloromethane.
  • a preferred C 6-8 aromatic hydrocarbon is benzene, toluene or xylol, more preferably toluene.
  • the C 1-4 nitroalkane is a C 1-2 nitroalkane, either nitromethane or nitroethane, more preferably nitromethane.
  • the C 1-4 alkyl cyanide is a C 1-2 alkyl cyanide, either acetonitrile or propionitrile, more preferably acetonitrile.
  • the anhydride is either trifluoroaceticanhydride or methyl chlorocarbonate, more preferably, trifluoroaceticanhydride.
  • indole-3-carboxylic acid is added drop-wise, more preferably, over a period of about 10 minutes to about 30 minutes, preferably about 15 minutes.
  • the catalyst is either a saturated trisubstituted amine or an aromatic amine.
  • the saturated trisubstituted amine is either a trialkyl amine or 4-dialkylaminopyridine amine.
  • the trisubstituted amine is 4-dimethylaminopyridine or diisopropylethylamine, more preferably, 4-dimethylaminopyridine.
  • HQO and the catalyst are added at the same time to a solution of the anhydride, the organic solvent and the 3-indole-carboxylic acid, providing a reaction mixture.
  • the reaction mixture is heated to a temperature of about 25° C. to about 40° C., more preferably to about 30° C. to about 35° C., for about 2 to about 18 hours, more preferably for about 2 hours, and preferably while stirring, providing Dolasetron base.
  • Dolasetron base may be recovered by removing the solvent to obtain a precipitate and filtering off the precipitate.
  • Dolasetron may be converted to Dolasetron salt by combining Dolasetron with an acid.
  • Dolasetron may be converted to Dolasetron mesylate monohydrate by combining Dolasetron, a mixture of acetone and water, and methane sulfonic acid.
  • Combining Dolasetron and the mixture of acetone and water provides a suspension, in which the solid dissolves when adding methane sulfonic acid. After complete dissolution, a precipitate of DLS-MsOH is obtained. The precipitate may be maintained in a fridge, and recovered by filtration, washing and drying.
  • TLC n-hexane-ethyl acetate 1:1, visualized by UV-light and/or iodine.
  • OAN solution in isobutyl acetate (1.2 L, containing 600 g of OAN) was combined with ethanol (1.2 L) at room temperature followed by the addition of (144 ml, 1 equiv) methanesulfonic acid, under stirring. The mixture was stirred for 3 hours. The salt was filtered, washed with a mixture of isobutyl acetate-ethanol 1:1 ( 12 ⁇ 300 ml) and dried.
  • Sodium borohydride (71 g, 1.4 equiv.) was dissolved in a mixture of water (500 ml) and aqueous solution of sodium hydroxide (30%, 14 ml).
  • OAN (361 g, 1.34 mol) was dissolved in methanol (3.6 L), and the solution was cooled to 0-5° C.
  • the solution of sodium borohydride was added drop-wise to the solution of OAN in methanol, and the mixture was stirred at 0-5° C. for about 1 hour.
  • the reaction was monitored by TLC (eluent:ethyl acetate). After completion of reaction acetic acid (80 ml) was added under stirring while cooling (foaming, warning and precipitating).
  • Indole-3-carboxylic acid (17.7 g, 1.1 equiv.) was added in portions to a solution of trifluoroacetic anhydride (20 ml, 1.4 equiv.) in a mixture toluene (360 ml) and trifluoroacetic acid (90 ml), at room temperature (20-25° C.), during 15 minutes. After 5-minutes of stirring, endo-5-hydroxy-8-azatricyclo[5.3.1.0 3,8 ]-undecan-10-one (18.12 g, 0.1 mol), was added in one portion. The reaction mixture heated to 30-35° C., the solid phase dissolved. The solution was stirred for 2 hours without external heating.
  • the trifluoroacetic acid was removed by evaporation under reduced pressure until starting of crystallization. 10% of an aqueous solution of sodium carbonate (360 ml) was added, then toluene was removed by evaporation under reduced pressure. The precipitated Dolasetron base monohydrate was collected by filtration, washed with water (3 ⁇ 60 ml), and dried overnight at 40° C. under reduced pressure. The dry product was weighed as 33.63 g (98%).
  • the dried crude Dolasetron base was dissolved in isobutyl acetate (1 L) at 95-100° C. Charcoal (1.7 g) was added to the solution, and after 10 minutes of stirring it was filtered off, and washed with isobutyl acetate (0.1 L). The solution was evaporated under reduced pressure to obtain a residue weighing 0.20-0.25 kg, which allowed to cool to room temperature, and then further cooled in a fridge overnight. The precipitated crystals were filtered off, washed with isobutyl acetate (2 ⁇ 20 ml), and dried overnight at 40-45° C. under reduced pressure. Yield was 88%.
  • Methanesulfonic acid (2.85 ml, 1 equiv) was added to a stirred suspension of Dolasetron base (14.24 g, 43.9 mmol) in a mixture of acetone-water 95:5 (100 ml). The solid dissolved immediately, after some minutes the salt precipitated in crystalline form. The mixture was put into fridge, after 4 hours the salt was filtered off, washed with same solvent mixture (2 ⁇ 15 ml), dried overnight in an air-ventilated oven at 40° C. The yield was 15.63 g (81%).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates. Intermediates for preparing Dolasetron according to the invention include 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compounds (SAN compounds) and endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one compounds (SQO compounds).

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application claims the benefit of the following U.S. Provisional Patent Application No. 60/756,690, filed Jan. 5, 2006; 60/800,884, filed May 15, 2006; 60/838,758, filed Aug. 17, 2006; 60/861,354, filed Nov. 27, 2006; 60/802,842, filed May 22, 2006; 60/818,934, filed Jul. 5, 2006; 60/833,515, filed Jul. 24, 2006; 60/836,432, filed Aug. 7, 2006; 60/763,683, filed Jan. 30, 2006; 60/784,248, filed Mar. 20, 2006; 60/815,199, filed Jun. 19, 2006; 60/852,887, filed October 18, 2006. The contents of these applications are incorporated herein by reference.
  • FIELD OF THE INVENTION
  • The present invention relates to an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate, and intermediates thereof.
  • BACKGROUND OF THE INVENTION
  • Dolasetron mesylate monohydrate, (2′,6α,8α,9αβ)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate monohydrate, (referred to as DLS-MsOH—H2O) a compound having the chemical structure,
    Figure US20070203175A1-20070830-C00001
  • Dolasetron Mesylate Monohydrate
  • is a serotonin receptor (5-HT3) antagonist used as an antiemetic and antinauseant agent in chemo- and radiotherapies.
  • DLS-MsOH-H2O developed by Merrell Dow Pharmaceuticals is marketed as tablets for oral administration and as sterile solution for intravenous administration by Aventis, under the name Anzemet®.
  • DLS-MsOH and its monohydrate form can be prepared by a multi step synthesis, as described in EP patent No. 0339669 (“the EP '669 patent”) as illustrated in the following scheme
    Figure US20070203175A1-20070830-C00002
  • Accordingly, step (c) of the reaction involves oxidation with a molar equivalent of an expensive oxidizing reagent, 3-chloroperbenzoic acid (referred to as mCPBA), which transforms to 3-chlorobenzoic acid (referred to as mCBA), waste that is disposed at the end of the reaction. Removal of mCBA is problematic, hence, leading to a contaminated product. CCA-epoxide is also contaminated by other aromatic impurities, such as [(3-ClPh)C(O)O]2 (the corresponding peroxide ) in an amount of 5%. Therefore, the oxidation reaction as described above is non-economic for scale-up. Also, the reaction in steps (e) and (f) are done by using periodic acid in ethyl acetate in step (e), and water as a solvent in step (f). Since, the reagents and the reduction products have low solubility in ethylacetate; the reaction disclosed in the above patent is slower. Also, the reaction in ethylacetate is more dangerous. In addition, since two different solvents are used in steps (e) and (f), a work-up procedure, which can lead to a decomposition of the sensitive 3-methoxycarbonyl-1,5-glutardialdehyde (the product of the oxidation step), is required.
  • A similar process is apparently described in EP patent No. 0266730, comprising an oxidation reaction, as described in step (c) of the above scheme, to the corresponding diol, instead of to the epoxide, as apparently disclosed in EP patent No. 0339669. The diol is then transformed to DLS-base in a similar way.
  • Hence, there is a need in the art for an improved process for the preparation of Dolasetron salts, preferably, Dolasetron Mesylate.
  • SUMMARY OF THE INVENTION
  • In one embodiment, the present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (referred to as an OAN compound salt) of formula Vs;
    Figure US20070203175A1-20070830-C00003

    wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • In another embodiment, the present invention provides crystalline methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one (referred to as OAN-MsOH).
  • In yet another embodiment, the present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound (referred to as a HAN compound salt) of formula VIs;
    Figure US20070203175A1-20070830-C00004

    wherein R1, R2 and Z are described before.
  • In one embodiment, the present invention provides crystalline methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol (referred to as HAN-MsOH).
  • In yet another embodiment, the present invention provides a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (referred to as a SAN compound) of formula X;
    Figure US20070203175A1-20070830-C00005

    wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • In one embodiment, the present invention provides an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-4-alkoxycarbonyl-8-trialkylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) compound (referred to as a SQO compound) of formula XII
    Figure US20070203175A1-20070830-C00006

    wherein R is a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • In another embodiment, the present invention provides crystalline endo-9-methoxycarbonyl-5-tert-butyldimethylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-4-methoxycarbonyl-8-tert-butyldimethylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as SQO).
  • In yet another embodiment, the present invention provides a quaternary ammonium salt of endo-5-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as a HQO-salt) of formula IIs;
    Figure US20070203175A1-20070830-C00007

    wherein Y is an acid selected from the group consisting of hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids.
  • In one embodiment, the present invention provides a process for the preparation of a CCA-epoxide of formula IV
    Figure US20070203175A1-20070830-C00008

    comprising combining a CCA-ester of formula III,
    Figure US20070203175A1-20070830-C00009

    an oxidizing agent selected from a group consisting of hydroperoxide, dialkyl peroxide, peroxyacid, peroxyester, diacyl peroxide, persulphate, perborate, and perphosphate, a catalyst, and a solvent selected from the group consisting of water, a water miscible organic solvent, and mixtures thereof, to obtain a CCA-epoxide of formula IV; wherein, R1 is C1-6 alkyl or C6-8 aryl, preferably, C1-4 alkyl, more preferably, methyl.
  • In another embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs,
    Figure US20070203175A1-20070830-C00010

    comprising preparing a CCA-epoxide of formula IV by the process of the invention; and converting it to a DLS-salt of formula VIIIs, wherein X is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, preferably, methane sulfonic acid.
  • In yet another embodiment, the present invention provides a process for the preparation of an OAN compound of formula V
    Figure US20070203175A1-20070830-C00011

    comprising combining a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, a water miscible organic solvent, and mixtures thereof, to form a reaction mixture; raising the pH of the reaction mixture; and adding to the resulting product a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3-acetonedicarboxylic acids, acetone and C1-4 esters thereof, to form an OAN compound of formula V, wherein R1 and R2 are independently, C1-6 alkyl or C6-8 aryl, preferably, C1-4 alkyl, more preferably, methyl.
  • In one embodiment, the present invention provides a process for the 10 preparation of a DLS-salt of formula VIIIs, comprising preparing an OAN compound of formula V by the process of the invention; and converting it to a DLS-salt of formula VIIIs.
  • In another embodiment, the present invention provides a process for the preparation of an OAN compound salt of formula Vs
    Figure US20070203175A1-20070830-C00012

    comprising combining an OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof to form an OAN salt; wherein R1 and R2 are independently, C1-6 alkyl or C6-8 aryl, preferably, C1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • In yet another embodiment, the present invention provides a process for purifying an OAN compound of formula V comprising combining an OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof; and adding a base to obtain a purified OAN compound.
  • In one embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing an OAN compound salt of formula Vs by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In another embodiment, the present invention provides a process for the preparation of a HAN compound of formula VI
    Figure US20070203175A1-20070830-C00013

    comprising combining an OAN compound salt of formula Vs, a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, forming a HAN compound of formula VI.
  • In yet another embodiment, the present invention provides a process for the preparation of a HAN compound salt of formula VIs
    Figure US20070203175A1-20070830-C00014

    comprising combining a HAN compound of formula VI,
    Figure US20070203175A1-20070830-C00015

    an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide and mixtures thereof, forming a HAN salt, wherein, Z is an acid, preferably methanesulfonic acid, R1 and R2 are independently, C1-6 alkyl or C6-8 aryl, preferably, C1-4 alkyl, more preferably, methyl.
  • In yet another embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing a HAN compound of formula VI by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In one embodiment, the present invention provides a process for purifying a HAN compound of formula VI comprising combining a HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof; and adding a base to obtain a purified HAN compound.
  • In another embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing a HAN compound salt of formula VIs by the process of the invention, and converting it to a DLS-salt of form.
  • In yet another embodiment, the present invention provides a process for the preparation of a SAN compound of formula X
    Figure US20070203175A1-20070830-C00016

    comprising combining a HAN-salt of formula VIs
    Figure US20070203175A1-20070830-C00017

    a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to obtain the SAN compound of formula X, wherein R1 and R2 are independently, C1-6 alkyl or C6-8 aryl, preferably, C1-4 alkyl, more preferably methyl, R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or together are a tert-butyldialkyl, preferably tert-butyldimethyl, and Z is an acid, preferably methanesulfonic acid.
  • In one embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a SAN compound of formula X by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In another embodiment, the present invention also provides a process for the preparation a SQO compound of formula XII
    Figure US20070203175A1-20070830-C00018

    comprising mixing a SAN compound of formula X, a metal alkoxide, and a polar aprotic organic solvent to form a mixture; heating the mixture; and reacting it with a weak acid forming the SQO compound of formula XII, wherein, R is a C1-6 alkyl or C6-8 aryl, preferably a C1-4 alkyl, more preferably methyl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or together are a tert-butyldialkyl, preferably, tert-butyldimethyl.
  • In yet another embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a SQO compound of formula XII by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In one embodiment, the present invention also provides a process for preparing HQO of formula II
    Figure US20070203175A1-20070830-C00019

    comprising mixing a SQO compound of formula XII, water and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids to obtain HQO of formula II.
  • In another embodiment, the present invention further provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing HQO of formula II by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In yet another embodiment, the present invention provides another process for the preparation of a HQO-salt of formula IIs comprising combining HQO, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acids, forming a HQO salt of formula IIs.
  • In one embodiment, the present invention provides a process for purifying HQO of formula II comprising a) combining HQO of formula II, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acids; and b) adding a base, to obtain a purified HQO of formula II.
  • In one embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising preparing a HQO-salt of formula IIs by the process of the invention, and converting it to a DLS-salt of formula VIIIs.
  • In yet another embodiment, the present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising the steps of a) combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form a first intermediate mixture; b) adding to the first intermediate mixture an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent, to form a second intermediate mixture; c) raising the pH of the second intermediate mixture; d) reacting the products in the second reaction mixture with a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3 acetonedicarboxylic acids, acetone and a C1-4 ester thereof, to form a third reaction mixture; e) adding to the third intermediate mixture a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form a fourth intermediate mixture; f) adding to the fourth intermediate mixture a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to form a fifth intermediate mixture; g) adding to the fifth intermediate mixture a metal alkoxide, and a polar aprotic organic solvent to form a sixth intermediate mixture; h) heating the sixth intermediate mixture; i) reacting the products in the sixth intermediate mixture with a weak acid forming a seventh intermediate mixture; j) adding to the seventh intermediate mixture water and an acid to form an eight intermediate mixture; k) mixing the eight intermediate mixture with an anhydride, 3-indole carboxylic acid, a halogenated hydrocarbon, and a catalyst; and 1) reacting the product from step k) with an acid to obtain the DLS-salt of formula VIIIs.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates powder X-ray diffraction pattern for OAN-MsOH.
  • FIG. 2 illustrates powder X-ray diffraction pattern for HAN-MsOH.
  • FIG. 3 illustrates powder X-ray diffraction pattern for SQO.
  • FIG. 4 illustrates powder X-ray diffraction pattern for HQO-HCl.
  • FIG. 5 illustrates powder X-ray diffraction pattern for HQO-CSA.
  • FIG. 6 illustrates powder X-ray diffraction pattern for HQO-base.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention offers novel intermediates in the syntheses of Dolasetron salts, and processes for preparing them. The invention also offers the use of these intermediates in novel processes for preparing Dolasetron salts, especially, the mesylate salt.
  • The present invention provides a process for the preparation of a DLS-salt of formula VIIIs, comprising the steps of a) combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form CCA-epoxide of formula IV; b) admixing CCA-epoxide with an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent; c) raising the pH of the mixture; d) admixing the mixture with a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3 acetonedicarboxylic acids, acetone and a C1-4 ester thereof, to form OAN of formula V; e) admixing the material of the previous step with a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form HAN of formula VI; f) admixing the material of the previous step with a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to form SAN of formula X; g) admixing the material of the previous step with a metal alkoxide, and a polar a-protic organic solvent to form a reaction mixture; h) heating the reaction mixture; i) quenching the reaction mixture with a with a weak acid forming SQO of formula XII; j) admixing the material of the previous step with a solvent selected from a group consisting of: water, and water-immiscible organic solvent, and an acid to form HQO of formula II; k) admixing the material of the previous step with an anhydride, 3-indole carboxylic acid, a halogenated hydrocarbon, and a catalyst to obtain Dolasetron base; and 1) reacting Dolasetron base with an acid to obtain the DLS-salt of formula VIIIs. Preferably, the weak acid in step i) is selected from the group consisting of acetic acid, formic acid, acetic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, and salicylic acid. Preferably, the acid in step j) is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids. Preferably, the acid in step l) is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, preferably, methane sulfonic acid. In the alternative, the weak acid in step i) can be a (strong) acid as in step j), in which instant the step j) of this process may be omitted.
  • The process can be illustrated by the following scheme:
    Figure US20070203175A1-20070830-C00020
  • The present invention provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (referred to as an OAN-salt) of formula Vs;
    Figure US20070203175A1-20070830-C00021

    wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and Z is an acid, preferably, methanesulfonic acid.
  • When R1 and R2 are methyl, and Z is methanesulfonic acid, said compound of formula Vs refers to the methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one (referred to as OAN-MsOH) of the following formula.
    Figure US20070203175A1-20070830-C00022
  • The present invention further provides crystalline OAN-MsOH. The crystalline OAN-MsOH of the present invention may be characterized by a powder XRD diffraction pattern having peaks at about 8.5, 18.0, and 20.9 degrees two-theta, ±0.2 degrees two-theta. Crystalline OAN-MsOH may be further characterized by a powder XRD diffraction pattern having peaks at about 14.7, 22.7, 24.3, 25.0, 26.3 and 27.9 degrees two-theta, ±0.2 degrees two-theta. Crystalline OAN-MsOH may be also substantially identified by the PXRD pattern as depicted in FIG. 1.
  • The present invention also provides a quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol compound (referred to as a HAN-salt) of formula VIs;
    Figure US20070203175A1-20070830-C00023

    wherein R1, R2 and Z are described before.
  • When R1 and R2 are methyl, and Z is methanesulfonic acid, said compound of formula VIs refers to the methanesulfonate salt of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane3-ol (referred to as HAN-25 MsOH) of the following formula.
    Figure US20070203175A1-20070830-C00024
  • The present invention provides crystalline HAN-MsOH. The crystalline HAN-MsOH of the present invention may be characterized by a powder XRD diffraction pattern having peaks at about 7.3, 11.6, and 14.6 degrees two-theta, ±0.2 degrees two-theta. The crystalline HAN-MsOH may be further characterized by a powder XRD diffraction pattern having peaks at about 15.9, 17.9, 19.0, 20.4, 21.9, 29.0 and 29.4 degrees two-theta, ±0.2 degrees two-theta. The crystalline HAN-MsOH may be also substantially identified by the PXRD pattern as depicted in FIG. 2.
  • The present invention further provides a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (referred to as a SAN compound) of formula X;
    Figure US20070203175A1-20070830-C00025

    wherein R1 and R2 are described before.
  • When R1 and R2 are methyl, and R3R4R5 is tert-butyldimethyl, said compound of formula X refers to 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-3-tert-butyldimethylsilyloxy-9-azabicyclo[3.3.1]nonane (referred to as SAN) of the following formula.
    Figure US20070203175A1-20070830-C00026
  • The present invention also provides an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-4-alkoxycarbonyl-8-trialkylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) compound (referred to as a SQO compound) of formula XII
    Figure US20070203175A1-20070830-C00027

    wherein R is a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, preferably, tert-butyldialkyl, more preferably, tert-butyldimethyl.
  • Preferably, when R is methyl and R3R4R5 is tert-butyldimethyl, said compound of formula XII refers to endo-9-methoxycarbonyl-5-tert-butyldimethylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-4-methoxycarbonyl-8-tert-butyldimethylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as SQO) of the following formula.
    Figure US20070203175A1-20070830-C00028
  • The present invention provides crystalline SQO. The crystalline SQO of the present invention may be characterized by an XRD diffraction pattern having peaks at about 5.1, 10.1, 12.7, and 20.3 degrees two-theta, ±0.2 degrees two-theta. The crystalline SQO may be further characterized by an XRD diffraction pattern having peaks at about 15.2, 17.0, 17.6, 18.3, 19.1, and 19.8 degrees two-theta, ±0.2 degrees two-theta. The crystalline SQO may be also substantially identified by the PXRD pattern as depicted in FIG. 3.
  • The present invention further provides a quaternary ammonium salt of endo-5-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one) (referred to as a HQO-salt) of formula IIs;
    Figure US20070203175A1-20070830-C00029

    wherein Y is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, preferably, methanesulfonic acid.
  • Preferably, when Y is HCl, said HQO-salt of formula IIs corresponds to HQO-HCl of the following formula.
    Figure US20070203175A1-20070830-C00030
  • The present invention provides crystalline HQO-HCl salt. The crystalline HQO-HCl salt of the present invention may be characterized by a powder XRD diffraction pattern as depicted in FIG. 4.
  • The present invention also provides a process for the preparation of a CCA-epoxide of formula IV
    Figure US20070203175A1-20070830-C00031

    comprising combining a CCA-ester of formula III,
    Figure US20070203175A1-20070830-C00032

    an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a diacyl peroxide, a persulphate, a perborate, a perphosphate, and a dimethyldioxiran, a catalyst, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to obtain the CCA-epoxide of formula IV, wherein R1 is a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl.
  • When R1 is methyl, said CCA-ester of formula III corresponds to CCA-methylester of the following formula,
    Figure US20070203175A1-20070830-C00033

    and said CCA-epoxide of formula IV corresponds to CCA-epoxide of the following formula.
    Figure US20070203175A1-20070830-C00034
  • Preferably, the CCA-ester of formula III is combined with a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to obtain a solution.
  • Preferably, the water miscible organic solvent is selected from the group consisting of linear or branched C1-4 alcohols. Preferably, the C1-4 alcohol is a C1-3 alcohol, more preferably, a C1-2 alcohol, most preferably, methanol. In the alternative, a mixture of water and a water immiscible organic solvent may be used in the presence of a phase transfer catalyst. Preferably, the water immiscible organic solvent is selected from the group consisting of a C1-8 halogenated hydrocarbon, a C2-8 ester, a C2-8 ether and a C3-6 ketone. A preferred C1-8 halogenated hydrocarbon is a C1-4 halogenated hydrocarbon, more preferably a C1-2 halogenated hydrocarbon. Preferably, the C1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform, more preferably dichloromethane. A preferred C2-8 ester is a C2-6 ester, more preferably, a C4-6 ester. Preferably, the C4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate, more preferably ethyl acetate. A preferred C2-8 ether is a C2-6 ether, more preferably, a C4-6 ether. Preferably, the C4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether, more preferably tert-butyl methyl ether. A preferred C3-6 ketone is a C4-6 ketone. Preferably, the C4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone, more preferably 2-pentanone. The most preferred solvent is dichloromethane. Further, the phase transfer catalyst is preferably a quaternary ammonium salt, more preferably the phase transfer catalyst is tetrabutyl ammonium bromide.
  • Preferably, the solution is combined with an oxidizing agent selected from the group consisting of: a hydroperoxide, a dialkyl peroxide, a peroxyacid, a peroxyester, a diacyl peroxide, a persulphate, a perborate, a perphosphate, and a dimethyldioxiran, and a catalyst, to obtain a mixture.
  • Preferably, the hydroperoxide is RO—OH, wherein R is either H or an alkyl group. Preferably, the alkyl group is a C1-6 alkyl, more preferably t-butyl. A preferred dialkyl peroxide is RO—OR, wherein R is a C1-6 alkyl, preferably t-butyl. Preferably, the peroxyacid is RCO—O—OH. More preferably, the RCO—O—OH is selected from the group consisting of: peracetic acid, trifluoroperacetic acid, perlauric acid, perbenzoic acid, and 3,5-dinitroperbenzoic acid. Preferably, the peroxyester is RCO—O—OR′, wherein R is phenyl or methyl, and R′ is an C1-6 alkyl, preferably t-butyl. A preferred diacyl peroxide is RCO—O—O—COR, wherein R is phenyl or methyl. A preferred persulphate is peroxydisulphuric acid (M2S2O8) in the form of a potassium, sodium or ammonium (M=K, Na, NH4) salt, peroxymonosulfuric acid (Caro's acid), and Oxone® (potassium monopersulfate triple salt: KHSO5—KHSO4—K2SO4 (2:1:1)”). The more preferred oxidizing agent is hydroperoxide, most preferably, hydrogen peroxide. Preferably, an aqueous solution of hydrogen peroxide is used. A preferred concentration of the solution is of about 3% to about 50%, more preferably of about 20% to about 40%, most preferably of about 30% to about 35%.
  • Preferably, the catalyst is selected from the group consisting of Zeolites and polyoxometalates. Preferably, the metal moiety of the polyoxometalates is selected from the group consisting of tungsten, molybdenum, rhenium, vanadium and niobium. More preferably, the catalyst is either sodium tungstate dihydrate or sodium molybdenate dihydrate.
  • A preferred amount of the catalyst is about 0.01 mole % to about 50 mole % per mole of the CCA-ester, more preferably about 1 mole % to about 10 mole % per mole of the CCA-ester, most preferably about 2 mole % per mole of the CCA-ester.
  • In preparing the CCA epoxide of formula IV, the reaction mixture is maintained at a temperature of about 0° C. to about 80° C., preferably about 30° C. to about 80° C., more preferably, at a temperature of about 15° C. to about 65° C., most preferably at a temperature of about 60° C. to about 65° C. The reaction mixture is preferably, maintained at such temperature for a period of about 0.5 hours to about 24 hours, more preferably for about 1 to about 10 hours, most preferably for about 2 hours to about 4 hours.
  • The progress of the reaction may be monitored by gas-chromatography (referred to as GC) or by thin-layer chromatography (referred to as TLC). When monitored by TLC, an eluent of n-hexane and ethylacetate in a ratio of 1:1 may be used.
  • The process for preparing a CCA-ester of formula IV may further comprise a recovery step. The CCA-epoxide of formula IV may be recovered comprising the steps of adjusting the temperature of the reaction mixture to a temperature of about 20° C. to about 30° C.; extracting the product with a water immiscible organic solvent, preferably, dichloromethane; and evaporating the solvent.
  • The process for preparing a CCA-ester of formula IV may further comprise a process for converting it to a DLS-salt of formula VIIIs,
    Figure US20070203175A1-20070830-C00035

    wherein, X is an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, preferably, methane sulfonic acid. This conversion to a DLS salt of formula VIIIs may be carried out by the process of the invention or any other known process converting the CCA epoxide of formula IV to a DLS salt of formula VIIIs as described for example in EP 0339699, example 9.
  • When X is methane sulfonic acid, said DLS-salt of formula VIIIs corresponds to DLS-MsOH of the following formula.
    Figure US20070203175A1-20070830-C00036
  • The process of the present invention provides an OAN compound of formula V prepared by a process comprising an oxidation reaction followed by Robinson-Schöpf reaction, wherein both reactions are done in water, and therefore can be done concurrently, i.e., without isolation of the oxidation product, prior to the Robinson-Schöpf reaction. The oxidation applies the use of periodic acid in water, in which the reagents and the reduction products have high solubility; hence, the reaction is fast. Also, using water allows controlling the exothermic nature of the reaction, thus, reducing the danger.
  • The present invention further provides a process for the preparation of an OAN compound of formula V
    Figure US20070203175A1-20070830-C00037

    comprising combining a) a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to form a reaction mixture; b) raising the pH of the reaction mixture; c) and adding to the reaction mixture of step b) a pH 4 buffer, glycine C1-4 ester or salts thereof, and a substance comprising carbonyl moiety selected from the group consisting of 1,3-acetonedicarboxylic acid, acetone and a C1-4 ester thereof, to form the OAN compound of formula V, wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl.
  • When R1 and R2 are methyl, said OAN compound of formula V corresponds to OAN of the following formula.
    Figure US20070203175A1-20070830-C00038
  • Combining a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvents, and mixtures thereof, to form a reaction mixture; and raising the pH of the reaction mixture, may be designated as an oxidation reaction.
  • Preferably, combining a CCA-epoxide of formula IV with an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvent and mixtures thereof provides a first reaction mixture.
  • Preferably, the water miscible organic solvent is selected from the group consisting of: a nitrile, a ketone and an ether. A preferred nitrile is a C2-4 nitrile. Preferably, the C2-4 nitrile is acetonitrile, propionitrile or butyronitrile. A preferred ketone is a C3-6 ketone. Preferably, the C3-6 ketone is acetone, methyl ethyl ketone or diethyl ketone. Preferably, the ether is a cyclic ether. A preferred cyclic ether is THF, 1,4-dioxane or 1,3-dioxolane. The preferred solvent is water.
  • Preferably, the oxidizing agent is selected from the group consisting of: periodic acid and salts thereof, lead tetraacetate, cerium and ammonium nitrate (Ce(NH4)2(NO3)6). More preferably, the oxidizing agent is periodic acid. Preferably, the oxidizing agent is added in the form of a solution when the solvent is water.
  • Preferably, the first reaction mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably at a temperature of about 10° C. to about 15° C. Preferably, the first mixture is maintained for a period of about 0.5 hours to about 24 hours, and more preferably for about 1 to about 3 hours. Maintaining the first reaction mixture is preferably done while stirring.
  • The first reaction mixture is, preferably, acidic. Preferably, the pH of the acidic first reaction mixture is of about 0.5 to about 7, more preferably of about 0.5 to about 2.
  • Preferably, the pH of the maintained first reaction mixture is increased to about 2 to about 7. The pH is raised, preferably to about 3.5 to about 4.5. Preferably, the pH is raised by using a water immiscible base, more preferably either poly(4-vinylpyridine) or OH resins, and even more preferably, OH resins. The water immiscible base is, preferably, filtered off, more preferably through Celite, providing an aqueous solution of the product of the oxidation reaction. Preferably, adjusting the pH is performed at a temperature of about 15° C. to about 35° C., more preferably at about room temperature.
  • The reaction may be run stepwise or concurrently, i.e., without isolation of the oxidation product prior to the Robinson-Schöpf reaction. Preferably, the process is run concurrently.
  • Preferably, after adjusting the pH, a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising carbonyl moiety selected from the group consisting of a 1,3-acetonedicarboxylic acids, acetone and C1-4 esters thereof, are added to obtain a second reaction mixture.
  • Preferably, the pH 4 buffer is an amine-free buffer. Preferably, the amine-free buffer is selected from the group consisting of: a citric acid-sodium hydroxide-hydrochloric acid buffer, a citric acid-disodium hydrogenphosphate buffer, a sodium acetate-acetic acid buffer, a potassium diphthalate-sodium hydroxide buffer, sodium dihydrogen phosphate and potassium hydrogen phthalate. More preferably, the amine-free buffer is potassium hydrogen phthalate. Preferably, the buffer is used in an amount of about 1 to about 10 mole equivalents, more preferably about 2 to 5 mole equivalents, most preferably about 3 mole equivalents, per mole equivalent of the CCA-epoxide.
  • Preferably, the glycine C1-4 ester is a methyl ester. A preferred salt of the glycine C1-4 ester is glycine hydrochloride. More preferably, the glycine C1-4 ester or salts thereof, is glycin methylester hydrochloride.
  • Preferably, the C1-4 ester of 1,3-acetonedicarboxylic acid is selected from the group consisting of symmetrical and mixed C1-4 ester derivatives. The preferred substance comprising a carbonyl moiety is 1,3-acetonedicarboxylic acid.
  • Preferably, the second reaction mixture is maintained at a temperature of about 0° C. to about 60° C., more preferably, at about 10° C. to about 40° C., most preferably at about room temperature. The second mixture is maintained, preferably for about 10 to about 72 hours, and more preferably for about 12 to about 24 hours, most preferably for about 18 hours. Maintaining the second reaction mixture is preferably done while stirring.
  • The process for preparing the OAN compound of formula V may further comprise a recovery step. The recovery may be done by any known process. The OAN compound of formula V may be recovered by filtering off the undissolved solid particles from the second reaction mixture, preferably, through Celite, followed by washing with water, and combining the filtrate with an inorganic base to obtain a pH of about 7 to about 9, more preferably, of about 7.5 to about 8. Preferably, the inorganic base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate, more preferably is sodium bicarbonate. The basic filtrate is then extracted with a water immiscible organic solvent, preferably a C2-5 acetate, more preferably isobutylacetate, and the solvent is evaporated.
  • The present invention also provides a process for the preparation of a DLS-salt of formula VIIIs comprising preparing the OAN compound of formula V by the process of the invention, and converting it to a DLS-salt of formula VIIIs. This conversion to a DLS salt of formula VIIIs may be carried out by the process of the invention or any other known process converting an OAN compound of formula V to a DLS salt of formula VIIIs as described for example in EP 0339699, examples 4 and 9.
  • The present invention provides a process for the preparation of an OAN-salt of formula Vs
    Figure US20070203175A1-20070830-C00039

    comprising reacting the OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide and mixtures thereof, wherein, R1 and R2 are described before, and Z is an acid, preferably, methanesulfonic acid.
  • The present invention further provides a process for purifying the OAN compound of formula V comprising reacting the OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide and mixtures thereof; and adding a base.
  • The OAN compound of formula V used as a starting material may be a crude OAN compound or a concentrated solution of a crude OAN compound, obtained in the recovery process of the OAN compound.
  • Preferably, the OAN compound of formula V is dissolved in an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide and mixtures thereof, prior to adding the acid.
  • Preferably, the C1-4 alcohol is a C1-3 alcohol. Preferably, the C1-3 alcohol is methanol, n-propanol, isopropanol or ethanol. A preferred C2-8 ester is a C2-6 ester, more preferably, a C2-4 ester. A preferred C2-4 ester is ethyl acetate, propylacetate, n-butyl acetate, or isobutylacetate. A preferred linear, branched or cyclic C2-8 ether is a C2-7 ether, more preferably, a C2-5 ether. A preferred C2-5 ether is 1,4-dioxane, diisopropyl ether, t-butyl methyl ether or tetrahydrofuran. Preferably, the C3-6 ketone is a C3-5 ketone. Preferably, the C3-5 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone, 3,3-dimethyl-2-butanone or acetone. Preferably, the C5-8 aliphatic hydrocarbon is a C5-7 aliphatic hydrocarbon, more preferably, a C6-7 aliphatic hydrocarbon. A preferred C6-7 aliphatic hydrocarbon is either n-hexane, or n-heptane. A preferred C1-8 halogenated hydrocarbon is a C1-6 halogenated hydrocarbon, more preferably a C1-4 halogenated hydrocarbon, most preferably a C1-2 halogenated hydrocarbon. A preferred C1-2 halogenated hydrocarbon is dichloroethane, chloroform or dichloromethane. A preferred C1-4 nitroalkane is a C1-2 nitroalkane. Preferably, the C1-2 nitroalkane is nitromethane or nitroethane. Preferably, the C1-4 alkylcyanide is a C1-3 alkylcyanide. A preferred C1-3 alkylcyanide is either propionitrile or acetonitrile. A preferred C6-8 aromatic hydrocarbon is a C6-7 aromatic hydrocarbon. Preferably, the C6-7 aromatic hydrocarbon is toluene. A preferred C3-10 amide is a C3-6 amide. Preferably, the C3-6 amide is dimethylformamide. The more preferred solvent is a mixture of a C2-4 ester and a C1-3 alcohol, more preferably, of isobutylacetate and ethanol. Preferably, the mixture contains isobutylacetate and ethanol in a ratio of about 1:1, respectively.
  • Preferably, the acid is either an organic acid or an inorganic acid. The organic acid is selected from the group consisting of carboxylic acids and sulfonic acids. Preferably, the carboxylic acid is selected from the group consisting of: formic acid, acetic acid, propionic acid, trichloroacetic acetic, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids. More preferably, the carboxylic acid is tartaric acid. A preferred sulfonic acid is selected from the group consisting of: methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids. More preferably, the sulfonic acid is either methane sulfonic acid or camphorsulfonic acid. Preferably, the inorganic acid is selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and fluoroboric acid. The more preferred inorganic acid is hydrochloric acid. The more preferred acid is methane sulfonic acid.
  • Combining the OAN compound of formula V, the solvent and the acid provides a mixture. Preferably, the mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably, at a temperature of about 20° C. to about 50° C., most preferably at a temperature of about 30° C. to about 40° C. The mixture is preferably maintained at such temperature for about 1 hour to about 24 hours, and more preferably, for about 2 to about 12 hours. Maintaining the reaction mixture is preferably done while stirring.
  • Preferably, reacting the OAN compound with an acid provides the corresponding OAN-salt of formula Vs. Preferably, the OAN-salt of formula Vs precipitates from the reaction mixture. Preferably, in the process of purifying the OAN compound of formula V, the precipitate is reacted with a base providing the OAN compound of formula V back again. Preferably, the precipitate is recovered prior to reacting with a base.
  • Preferably, the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. More preferably, the base is sodium bicarbonate.
  • The process for preparing an OAN-salt of formula Vs may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • The present invention provides a process for the preparation of a HAN compound of formula VI
    Figure US20070203175A1-20070830-C00040

    comprising combining an OAN salt of formula Vs, a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof to obtain the HAN compound of formula VI.
  • Preferably, the OAN-salt of formula Vs is OAN-MsOH. When the OAN-salt is used as a starting material, it is combined with a water miscible organic solvent, providing a suspension. Preferably, the suspension is prepared at a temperature of about 15° C. to about 35° C., preferably of about 20° C. to about 25° C. Optionally, the OAN compound of formula V may be used as a starting material. When, the OAN compound of formula V is used as a starting material, it is combined with a water miscible organic solvent, providing a solution. Preferably, the water miscible organic solvent is a C1-4 alcohol, more preferably, a C1-3 alcohol, most preferably, a C1-2 alcohol. A preferred C1-2 alcohol is methanol.
  • Preferably, the reducing reagent is a metal hydride complex, preferably lithium borohydride, selectricde or sodium borohydride, more preferably, sodium borohydride. The reducing agent may be used in a basic aqueous solution or as a solid. When the OAN compound of formula V is the starting material, a basic aqueous solution of the reducing agent may be used. Preferably, the basic aqueous solution is an aqueous solution of an alkali hydroxide, more preferably an aqueous solution of sodium hydroxide. Preferably, the basic aqueous solution contains about 30% to about 50% by weight, preferably about 30%, of sodium hydroxide.
  • Preferably, the solution of the OAN compound of formula V in a C1-4 alcohol and the basic aqueous solution of the reducing agent are combined at a temperature of about 0° C. to about 10° C., preferably about 0° C. to about 5° C. Preferably, the solution of the reducing reagent is added drop-wise to the solution of the OAN compound in a C1-4 alcohol.
  • When the OAN-salt of formula Vs is the starting material, a solid reducing agent may be used. Preferably, the suspension of the OAN-salt of formula Vs in a C1-4 alcohol and the reducing agent are combined at a temperature of about 15° C. to about 35° C., preferably about 20° C. to about 25° C. Preferably, the reducing reagent is added portion-wise to the suspension of the OAN-salt in a C1-4 alcohol. Preferably, the portion-wise addition of the reducing agent is done while maintaining the temperature at about 15° C. to about 35° C., preferably about 25° C. to about 35° C.
  • Combining the above substances leads to a mixture. Preferably, the mixture is maintained for about a half hour to about 2 hours, preferably for about a half hour to about an hour at such temperature, prior to recovering the HAN compound of formula VI.
  • When the OAN compound of formula V is used as a starting material, the mixture is maintained at a temperature of about 0° C. to about 5° C., for about an hour, and when the starting material is OAN-salt of formula Vs, the mixture is maintained at a temperature of about 25° C. to about 35° C., for about a half an hour. The reaction may be monitored by TLC using ethylacetate as an eluent.
  • The process for preparing the HAN compound of formula VI may further comprise a recovery step. The recovery may be carried out by any known method. The HAN compound of formula VI may be recovered by a process comprising adding an acid, preferably a water miscible organic acid, more preferably acetic acid, to the reaction mixture, to give a precipitate. The precipitate is then combined with water and with a halogenated hydrocarbon, preferably a C1-2 halogenated hydrocarbon, to give a solution, optionally followed by filtration. The aqueous phase is then extracted, and the solvent is evaporated form the combined organic phase, providing a crude HAN compound. Optionally, after adding acetic acid, the mixture is evaporated and the residue is combined with ethylacetate. The undissolved particles are then, filtered off, and the filtrate is concentrated, providing a crude HAN compound.
  • The present invention further provides a process for the preparation of a HAN-salt of formula VIs,
    Figure US20070203175A1-20070830-C00041

    comprising reacting the HAN compound of formula VI,
    Figure US20070203175A1-20070830-C00042

    an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof, wherein, Z, R1 and R2 are described before.
  • When R1 and R2 are methyl, said HAN compound of formula VI corresponds to HAN of the following formula,
    Figure US20070203175A1-20070830-C00043

    and when R1 and R2 are methyl Z is methane sulfonic acid, said HAN-salt of formula VIs corresponds to HAN-MsOH of the following formula.
    Figure US20070203175A1-20070830-C00044
  • The process for preparing the HAN compound of formula VI may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • The present invention also provides a process for purifying the HAN compound of formula VI comprising combining the HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof; and adding a base.
  • The HAN compound of formula VI used as a starting material may be a crude HAN compound.
  • Preferably, the HAN compound of formula VI is dissolved in an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, linear, branched or cyclic C2-8 ethers, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof, prior to adding the acid.
  • Preferably, the C1-4 alcohol is a C1-3 alcohol. Preferably, the C1-3 alcohol is methanol, ethanol, n-propanol, or isopropanol. A preferred C2-8 ester is a C2-6 ester, more preferably a C4-6 ester. A preferred C4-6 ester is ethyl acetate, propyl acetate, butyl acetate, or isobutyl acetate. A preferred linear, branched or cyclic C2-8 ether is a C2-7 ether, more preferably a C2-6 ether. A preferred C2-6 ether is tetrahydrofuran, 1,4-dioxane, diisopropyl ether, or t-butyl methyl ether. Preferably, the C3-6 ketone is a C3-5 ketone. Preferably, the C3-5 ketone is acetone, methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone, or 3,3-dimethyl-2-butanone. Preferably, the C5-8 aliphatic hydrocarbon is a C5-7 aliphatic hydrocarbon, more preferably a C6-7 aliphatic hydrocarbon. A preferred C6-7 aliphatic hydrocarbon is either n-hexane, or n-heptane. A preferred C1-8 halogenated hydrocarbon is a C1-6 halogenated hydrocarbon, more preferably a C1-4 halogenated hydrocarbon, most preferably a C1-2 halogenated hydrocarbon. A preferred C1-2 halogenated hydrocarbon is dichloromethane, dichloroethane, or chloroform. A preferred C1-4 nitroalkane is a C1-2 nitroalkane. Preferably, the C1-2 nitroalkane is nitromethane or nitroethane. Preferably, the C1-4 alkylcyanide is a C1-3 alkylcyanide. A preferred C1-3 alkylcyanide is either acetonitrile or propionitrile. A preferred C6-8 aromatic hydrocarbon is a C6-7 aromatic hydrocarbon. Preferably, the C6-7 aromatic hydrocarbon is toluene. A preferred C3-10 amide is a C3-6 amide. Preferably, the C3-6 amide is dimethylformamide. The more preferred solvent for dissolving the HAN compound of formula VI is a C2-4 ester, most preferably, ethylacetate.
  • Preferably, the acid is the same as the acid in the process for preparing the purified OAN compound of formula V. The more preferred acid is methane sulfonic acid.
  • Combining the HAN compound of formula VI, the solvent and the acid provides a mixture. Preferably, the mixture is maintained at a temperature of about 10° C. to about 60° C., more preferably, at a temperature of about 20° C. to about 50° C., most preferably at a temperature of about 30° C. to about 40° C. The mixture is preferably maintained at such temperature for about 0.5 hours to about 24 hours, and more preferably for about 1 hour to about 3 hours, most preferably for about 2 hours. Maintaining the reaction mixture is preferably done while stirring.
  • Preferably, reacting the HAN compound with an acid provides a corresponding HAN-salt of formula VIs. Preferably, the HAN-salt of formula VIs precipitates from the reaction mixture. Preferably, in a process for purifying the HAN compound of formula VI, the HAN-salt of formula VIs is reacted with a base, providing the HAN compound of formula VI back again. Preferably, the precipitate is recovered prior to reacting with a base.
  • Preferably, the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. More preferably, the base is sodium bicarbonate.
  • The process for preparing a HAN-salt of formula VIs may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • The present invention further provides a process for the preparation of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]-nonane compound (referred to as a SAN compound) of formula X
    Figure US20070203175A1-20070830-C00045

    wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, preferably, a C1-4 alkyl, more preferably, methyl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, preferably, tert-butyldialkyl, more preferably, tert-butyldimethyl comprising combining a HAN compound of formula VI or a salt thereof
    Figure US20070203175A1-20070830-C00046

    a silylating agent selected from the group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), silazanes, a base, and an a-protic organic solvent forming a mixture to obtain the SAN compound of formula X, wherein, R1 and R2 and Z are described before.
  • When R1 and R2 are methyl, and Z is MsOH, said compound of formula VIs corresponds to HAN-MsOH of the following formula,
    Figure US20070203175A1-20070830-C00047

    and said compound of formula X corresponds to SAN of the following formula.
    Figure US20070203175A1-20070830-C00048
  • Preferably, the HAN-salt of formula VI is combined with an a-protic organic solvent. Preferably, the a-protic organic solvent is selected from a group consisting of a C1-8 halogenated hydrocarbon, a C2-8 ester, a C2-8 ether, C6-8 aromatic hydrocarbon, C3-10 amide, and a C3-6 ketone to obtain a suspension. A preferred C1-8 halogenated hydrocarbon is a C1-5 halogenated hydrocarbon, more preferably, a C1-3 halogenated hydrocarbon. Preferably, the a C1-3 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform. A preferred C2-8 ester is a C4-6 ester. Preferably, the C4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate. A preferred C2-8 ether is a C4-6 ether. Preferably, the C4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether. A preferred C6-8 aromatic hydrocarbon is a C6-7 aromatic hydrocarbon. Preferably, the C6-7 aromatic hydrocarbon is toluene. A preferred C3-10 amide is a C3-6 amide. Preferably, the C3-6 amide is dimethylformamide. A preferred C3-6 ketone is a C4-6 ketone. Preferably, the C4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone. The preferred solvent is dichloromethane.
  • The base is added to the suspension, providing a solution. Preferably, about 2 to about 10 mole equivalent of base per mole equivalent of the HAN-salt is used. More preferably, about 3 to about 6 mole equivalent of base per mole equivalent of the HAN-salt is used. Preferably, the base is selected from the group consisting of: sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate potassium bicarbonate, trialkyl amines, and N-containing heterocycles. Preferably, the trialkylamine is triethylamine, diisopropylethyl amine or tributyl amine. A preferred N-containing heterocycle is piperidine, pyridine, pyrimidine, piperazine, triazine, pyrrolidine, imidazole, or triazole. The preferred base is an N-containing heterocycle, more preferably, imidazole.
  • Preferably, the base is added at a temperature of about 15° C. to about 55° C., more preferably, at 20° C. to about 25° C.
  • Preferably the silane is selected from the groups consisting of triethylsilane, triisopropylsilane, and triphenylsilane. Preferably the silyl halogendie is selected from the group consisting of trimethylsily chloride, tert-butyldimethylsilyl chloride, and tert-butyldiphenylsilyl chloride. Preferably the silyl cyanide is selected from the group consting of trimethylsilyl cyanide, triethylsilyl cyanide, and tert-butyldimethylsilyl cyanide. Preferably the silyl amine is trimethylsilyldiethylamine or triethylsilyldiethylamine. Preferably the silyl amide is selected from the group consisting of N-methyl-N-trimethylsilylacetamide, N-methyl-N-triethylsilylacetamide, and tert-butyldimethylsilyl-N-methyltrifluoroacetamide. Preferably the silyl triflate is selected from the group consisting of trimethylsilyl trifluoromethanesulfonate, triethylsilyl trifluoromethanesulfonate, and tert-butyldimethylsilyl trifluoromethanesulfonate. Preferably the silazane is hexamethyldisilazane or hexaethyldisilazane. Preferably, the silylating agent is trialkylsilyl halogenide. Preferably, the alkyl group is t-butyldimethyl. The preferred silylating agent is tert-butyldimethylsilyl chloride. Preferably, the silylating agent is added to the solution, providing a reaction mixture.
  • Preferably, about 1 to about 4 mole equivalent of silylating agent per mole equivalent of the HAN-salt is used. More preferably, about 1.5 to about 2.5 mole equivalent of sylilating agent per mole equivalent of the HAN-salt is used. Preferably, the mixture is maintained at a temperature of about 0° C. to about 80° C., more preferably, more preferably at a temperature of about 20° C. to about 60° C., most preferably, at about 40° C. to about 60° C. Preferably, the mixture is maintained for about 0.5 hours to about 24 hours, and more preferably, for about 4 to about 12 hours.
  • The progress of the reaction may be monitored by HPLC or by TLC. When monitored by TLC, an eluent of ethyl acetate is used.
  • The process for preparing the SAN compound of formula X may further comprise a recovery step. The SAN compound of formula X may be recovered by extracting the product with water, and evaporating the solvent.
  • The SAN compound of formula X may also be prepared from the HAN compound of formula VI
    Figure US20070203175A1-20070830-C00049

    using similar conditions as used when the HAN-salt of formula VIs is the starting material, however, a smaller amount of base and of a silylated agent may be used and the most preferred solvent is dichloromethane. Preferably, when the HAN compound of formula VI is the starting material, about 1 to about 5 mole equivalent of base per mole equivalent of the HAN compound is used, more preferably, about 1 to about 3 mole equivalent of base per mole equivalent of the HAN compound is used. Preferably, about 1 to about 3 mole equivalent of silylating agent per mole equivalent of the HAN compound is used. More preferably, about 1 to about 2 mole equivalent of silylating agent per mole equivalent of the HAN compound is used.
  • The process for preparing the SAN compound of formula X may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • The present invention provides a process for the preparation of a SQO compound of formula XII
    Figure US20070203175A1-20070830-C00050

    comprising mixing a SAN compound of formula X, a metal alkoxide, and a polar a-protic organic solvent to form a mixture; heating the mixture; and reacting this mixture with a weak acid, forming the SQO compound of formula XII, wherein, R, R3R4 and R5 are described before.
  • When R is methyl, and R3R4R5 are tert-butyldimethyl said compound of formula XII corresponds to SQO of the following formula.
    Figure US20070203175A1-20070830-C00051
  • A preferred polar a-protic organic solvent is selected from the group consisting of a C2-8 ether having a boiling point of about 60° C. to about 100° C. Preferably, the C2-8 ether having a boiling point of about 60° C. to about 100° C. is tetrahydrofuran (referred to as THF), 2-methyltetrahydrofuran, tetrahydropyran, monoglyme, diisopropyl ether, or methyl t-butyl ether. The more preferred polar aprotic organic solvent is THF.
  • Preferably, the SAN compound of formula X is dissolved in a polar a-protic organic solvent, prior to adding the metal alkoxide.
  • Preferably, the metal alkoxide is selected from the group consisting of lithium alcoholates, sodium alcoholates and potassium alcoholates; wherein the alcoholate moiety contains 1 to 4 carbons. More preferably, the metal alkoxide is potassium tert-butoxide.
  • Combining the SAN compound of formula X, the polar a-protic organic solvent and the metal alkoxide provides a solution. Preferably, the solution is heated to a temperature of about 40° C. to about 120° C., more preferably, to a temperature of about 60° C. to about 80° C. The solution is heated, preferably, for about 0.5 hours to about 8 hours, and more preferably, for about 1 hour to about 3 hours. Heating the solution is preferably done under stirring.
  • While heating, the solution is concentrated, preferably, by distillation of the polar a-protic organic solvent, providing a mixture. The mixture is, preferably, cooled to a temperature of about 0° C. to about 30° C., more preferably, to a temperature of about 15° C. to about 25° C., prior to reacting with the acid.
  • Preferably, the weak acid is selected from the group consisting of acetic acid, formic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids. Preferably, the acid is a water miscible organic acid, preferably acetic acid, more preferably acetic acid combined with water, providing a diluted aqueous solution of acetic acid. Preferably, the acid is added to the cooled mixture, providing an acidic mixture, prior to recovering the SQO compound of formula XII. Preferably, the pH of the acidic mixture is of about 4 to about 6, more preferably, of about 5 to about 6.
  • The process for preparing the SQO compound of formula XII may further comprise a step of recovering it. The recovery may be carried out by any known method. The SQO compound of formula XII may be recovered by a process comprising combining the acidic mixture with a base, providing a slight basic mixture; concentrating the slight basic mixture; precipitating the SQO compound of formula XII; and recovering it.
  • Preferably, the pH of the slightly basic mixture is of about 7 to about 8. Preferably, the base is selected from a group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. The more preferred base is sodium bicarbonate.
  • Preferably, the basic mixture is concentrated by removing the polar a-protic organic solvent. Preferably, removal of the polar a-protic organic solvent is done by distillation. The removal of the polar a-protic organic solvent provides a concentrated aqueous mixture. Preferably, the precipitation of the SQO compound of formula XII is done by cooling the concentrated aqueous mixture to about 0° C. to about 10° C., preferably about 2° C. to about 8° C. The cooled concentrated aqueous mixture is maintained, preferably, for about 3 hours to about 24 hours, and more preferably, for about 8 hours to about 18 hours, prior to filtering the precipitate. The filtered SQO compound of formula XII is washed with water, and dried.
  • The process for preparing the SQO compound of formula XII may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • The present invention also provides a process for preparing HQO of formula II
    Figure US20070203175A1-20070830-C00052

    comprising mixing a SQO compound of formula XII, a solvent selected from the group consisting of water and a water-miscible organic solvent, and an acid to obtain HQO.
  • Preferably, the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids.
  • Preferably, the SQO compound of formula XII is combined with water or a water-miscible organic solvent to obtain a suspension. Preferably, the water-miscible organic solvent is dimethylformamide, dimethylacetamide, dimethyl sulfoxide, or diglyme, more preferably dimethylformamide. Preferably, the SQO compound of formula XII is combined with water at a temperature of about 10° C. to about 50° C., more preferably, at 20° C. to about 25° C.
  • Preferably, the acid is added to the suspension providing a solution. Preferably, the addition of the acid provides an acidic solution. Preferably, the acidic solution has a pH of about 0.5 to about 3, more preferably, of about 1 to about 2.
  • The acidic solution is heated, preferably, to a temperature of about 80° C. to about 100° C. The heated solution is maintained, preferably, for about 3 hours to about 24 hours, and more preferably, for about 6 hours to about 10 hours. Heating the solution is preferably done while stirring.
  • The progress of the reaction may be monitored by HPLC or by TLC. When monitored by TLC, an eluent of methylene chloride and methanol in a ratio of 1:1 is used.
  • The process for preparing HQO of formula II may further comprise a recovery step. The recovery may be carried out by any known method. HQO of formula II may be recovered by cooling the heated acidic solution, adding a base to the cooled acidic mixture, extracting the product with a water immiscible organic solvent, and evaporating the water immiscible organic solvent to obtain HQO of formula II.
  • Preferably, the heated solution is cooled to a temperature of about 0° C. to about 30° C., more preferably, to a temperature of about 15° C. to about 25° C.
  • Preferably, a base is added to the cooled solution. Preferably, the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. The more preferred base is sodium hydroxide. Preferably, the addition of the base provides a basic mixture. Preferably, the basic mixture has a pH of about 8 to about 13, more preferably, of about 11 to about 12.
  • The preferred water immiscible organic solvent is selected from the group consisting of a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone and a C5-8 aliphatic hydrocarbon, and a C1-8 halogenated hydrocarbon. The most preferred water immiscible organic solvent is methylene chloride. A preferred C2-8 ester is a C4-6 ester. Preferably, the C4-6 ester is ethyl acetate, n-butyl acetate or isobutyl acetate. A preferred C2-8 ether is a C4-6 ether. Preferably, the C4-6 ether is diethyl ether, diisopropyl ether or tert-butyl methyl ether. A preferred C3-6 ketone is a C4-6 ketone. Preferably, the C4-6 ketone is methyl ethyl ketone (2-butanone), 2-pentanone, 3-pentanone or 3,3-dimethyl-2-butanone. A preferred C5-8 aliphatic hydrocarbon is a C6-7 aliphatic hydrocarbon. Preferably, the C6-7 aliphatic hydrocarbon is n-hexane or n-heptane. A preferred C1-8 halogenated hydrocarbon is a C1-2 halogenated hydrocarbon. Preferably, the C1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform.
  • Optionally, HQO of formula II may be prepared directly from the SAN compound of formula X, i.e., without isolating the SQO compound of formula XII. Preferably, the reaction may include the same steps as described in the process for preparing the SQO compound of formula XII, but using a strong acid instead of a weak acid, and heating. Preferably, the stron acid is selected from the group consisting of methanesulfonic acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, and triflic acid.
  • This process for preparing HQO of formula II from the SQO compound of formula XII or directly from the SAN compound of formula X may further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • Preferably, reacting SAN with an acid provides the corresponding salt of HQO, a HQO-salt of formula IIs. Preferably, the HQO-salt of formula IIs precipitates in the reaction mixture. Preferably, the HQO-salt of formula IIs is reacted with a base, providing HQO of formula II back again. Preferably, the precipitate is recovered prior to reacting with a base.
  • Preferably, the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, and potassium bicarbonate, more preferably sodium bicarbonate.
  • The present invention also provides another process for the preparation of a HQO-salt of formula IIs comprising combining HQO, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acid to obtain a HQO salt of formula IIs.
  • The present invention provides a process for purifying HQO of formula II by a process comprising combining HQO of formula II, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acid forming a mixture, and adding a base to obtain purified HQO.
  • Preferably, the alcohol is a C1-4 alcohol, more preferably, ethanol.
  • Preferably, the acid is an organic acid, more preferably, a sulfonic acid, most preferably, methanesulfonic acid.
  • The process for preparing a HQO-salt of formula IIs can further comprise a process for converting it to a DLS-salt of formula VIIIs.
  • HQO-salt of formula IIs may be converted to a DLS-salt of formula VIIIs comprising converting it to the free base, HQO of formula II; reacting HQO with a base to form a reaction mixture; mixing the reaction mixture with an anhydride, indole-3-carboxylic acid, an organic solvent, and a catalyst to form a mixture; and reacting the mixture with an acid, to obtain the DLS-salt of formula VIIIs.
  • Preferably, the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. The more preferred base is sodium bicarbonate.
  • Preferably, the organic solvent is selected from the group consisting of a C1-2 halogenated hydrocarbon, a C6-8 aromatic hydrocarbon, a C1-4 nitroalkane, a C1-4 alkyl cyanide, trifluoroacetic acid and mixtures thereof. A preferred C1-2 halogenated hydrocarbon is dichloromethane, 1,2-dichloroethane or chloroform, more preferably dichloromethane. A preferred C6-8 aromatic hydrocarbon is benzene, toluene or xylol, more preferably toluene. Preferably, the C1-4 nitroalkane is a C1-2 nitroalkane, either nitromethane or nitroethane, more preferably nitromethane. Preferably, the C1-4 alkyl cyanide is a C1-2 alkyl cyanide, either acetonitrile or propionitrile, more preferably acetonitrile.
  • Preferably, the anhydride is either trifluoroaceticanhydride or methyl chlorocarbonate, more preferably, trifluoroaceticanhydride.
  • Preferably, indole-3-carboxylic acid is added drop-wise, more preferably, over a period of about 10 minutes to about 30 minutes, preferably about 15 minutes.
  • Preferably, the catalyst is either a saturated trisubstituted amine or an aromatic amine. Preferably, the saturated trisubstituted amine is either a trialkyl amine or 4-dialkylaminopyridine amine. Preferably, the trisubstituted amine is 4-dimethylaminopyridine or diisopropylethylamine, more preferably, 4-dimethylaminopyridine.
  • Preferably, HQO and the catalyst are added at the same time to a solution of the anhydride, the organic solvent and the 3-indole-carboxylic acid, providing a reaction mixture. Preferably, the reaction mixture is heated to a temperature of about 25° C. to about 40° C., more preferably to about 30° C. to about 35° C., for about 2 to about 18 hours, more preferably for about 2 hours, and preferably while stirring, providing Dolasetron base.
  • Dolasetron base may be recovered by removing the solvent to obtain a precipitate and filtering off the precipitate.
  • Dolasetron may be converted to Dolasetron salt by combining Dolasetron with an acid. Preferably, Dolasetron may be converted to Dolasetron mesylate monohydrate by combining Dolasetron, a mixture of acetone and water, and methane sulfonic acid.
  • Combining Dolasetron and the mixture of acetone and water provides a suspension, in which the solid dissolves when adding methane sulfonic acid. After complete dissolution, a precipitate of DLS-MsOH is obtained. The precipitate may be maintained in a fridge, and recovered by filtration, washing and drying.
  • Having thus described the invention with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification. The Examples are set forth to aid in understanding the invention but are not intended to, and should not be construed to limit its scope in any way.
  • EXAMPLES Example 1 Preparation of CCA-Epoxide of Formula IV
  • CCA-Me ester (37.8 g, 0.3 mol) was dissolved in 60 ml of methanol followed by the addition of hydrogen peroxide (30-35%, 43 ml, 1.3 equiv.) and sodium tungstate dihydrate (2 g, 2 mol %). The yellow reaction mixture was refluxed slightly (at 60-65° C.) for 2-4 hours until the reaction was completed (GC or TLC: eluent n-hexane-ethyl acetate 1:1, visualized by iodine). After cooling it was extracted with methylene chloride (3×100 ml). The combined organic phases were dried on sodium sulfate and evaporated to dryness. The product was 40.5 g colorless oil (95% yield).
  • Example 2 Preparation of OAN of Formula V
  • To a well-stirred solution of periodic acid (32 g, 0.14 mol) in water (200 ml) was added CCA-epoxide (19 g, 0.14 mol), and the reaction mixture was stirred at 10-15° C. for 1 hour. After completion, the reaction mixture having a pH of 1, was cooled and the pH was adjusted to 3.5-4 by the addition of OH-resin (or poly(4-vinylpyridine)), followed by stirring the mixture for 10-15 min at room temperature. The solid material was filtered through a layer of Celite and washed with water (2×150 ml). To the aqueous solution were added sequentially at room temperature (86 g, 0.42 mol, 3 equiv) potassium hydrogen phthalate, (21 g, 0.17 mol, 1.2 equiv) glycine methyl ester hydrochloride and (25 g, 0.17 mol, 1.2 equiv) 1,3-acetonedicarboxylic acid. The dark red reaction mixture was stirred at room temperature for 18 h (overnight). The undissolved solid was filtered through a layer of Celite, washed with a small volume of water (2×50 ml). To the solution was added, in portions, solid sodium hydrogen carbonate (until pH 7.5-8), then the solution was extracted with isobutyl acetate (5×200 ml). The combined organic phases were dried on sodium sulfate and evaporated to dryness or to a reduced volume of about 40 ml.
  • TLC: n-hexane-ethyl acetate 1:1, visualized by UV-light and/or iodine.
  • Example 3 Preparation of OAN-MsOH Salt of Formula Vs
  • Crude OAN (600 g) was dissolved in isopropanol (3 L) at room temperature followed by the addition of (144 ml, 1 equiv) methanesulfonic acid, under stirring. The mixture was warmed to 30-40° C., and stirred for overnight. The precipitated oil solidified. The salt was filtered at room temperature, washed with isopropanol (600+2×300 ml) and dried.
  • The overall yield (from CCA-epoxyide): 35-40% (purity: <90%).
  • Example 4 Preparation of OAN-MsOH Salt of Formula Vs
  • OAN solution in isobutyl acetate (1.2 L, containing 600 g of OAN) was combined with ethanol (1.2 L) at room temperature followed by the addition of (144 ml, 1 equiv) methanesulfonic acid, under stirring. The mixture was stirred for 3 hours. The salt was filtered, washed with a mixture of isobutyl acetate-ethanol 1:1 ( 12×300 ml) and dried.
  • The overall yield (from CCA-epoxyide): 35-40%.
  • Example 5 Preparation of HAN of Formula VI
  • Sodium borohydride (71 g, 1.4 equiv.) was dissolved in a mixture of water (500 ml) and aqueous solution of sodium hydroxide (30%, 14 ml). OAN (361 g, 1.34 mol) was dissolved in methanol (3.6 L), and the solution was cooled to 0-5° C. The solution of sodium borohydride was added drop-wise to the solution of OAN in methanol, and the mixture was stirred at 0-5° C. for about 1 hour. The reaction was monitored by TLC (eluent:ethyl acetate). After completion of reaction acetic acid (80 ml) was added under stirring while cooling (foaming, warning and precipitating). Water (0.5 L) and methylene chloride (1 L) were added (filtration can be necessary). The aqueous phase was extracted with (2×1 L) of methylene chloride. The combined organic phases were dried on sodium sulfate and evaporated to dryness. The yield was 70%.
  • Example 6 Preparation of HAN of Formula VI
  • (14.6 g, 40 mmol) OAN-MsOH was suspended at 20-25° C. in (300 ml) ethanol, then to this suspension (4.2 g, 2.8 equiv) sodium borohydride was added in portions in order to keep the inner temperature between 25-35° C. After addition of the reducing agent the reaction mixture was stirred for additional 30 minutes. The conversion was monitored by TLC (eluent:ethyl acetate), when it was complete (4.5 ml) acetic acid was added (pH 6-7) and the mixture was evaporated to dryness on rotavapor at 35-40° C. The residue was mixed with ethyl acetate (60 ml), the unsolved material was filtered off and the filtered material was washed with ethyl acetate (2×20 ml). The filtrate was concentrated on rotavapor at 35-40° C., to obtain 10.2 g (94%) of crude HAN.
  • Example 7 Preparation of HAN-MsOH Salt of Formula VIs
  • Crude HAN (17 g) was dissolved in ethyl acetate (100 ml) at room temperature and (3.6 ml, 1.1 equiv) of methanesulfonic acid was added under stirring. The mixture was heated to 30-40° C., and was stirred for 2 hours. The precipitated oil solidified. The salt was filtered at room temperature, washed with ethyl acetate (2×30 ml) and dried. Yield was 80%.
  • Example 8 Preparation of HQO—CSA Salt of Formula IIs
  • To a solution of HQO (0.18 g, 1 mmol) in (3 ml) ethanol was added camphorsulfonic acid (0.23 g) in (2.5 ml) ethanol. The mixture was stirred for 20 minutes, filtered, then the solid material was washed with ethyl acetate and dried.
  • Example 9 Example 13: Preparation of DLS-Base with Catalyst
  • To a solution of 52.9 ml (1.3 equiv) trifluoroacetic anhydride in 1.0 L of dry dichloromethane 47.5 g (1.3 equiv) indole-3-carboxylic acid was added in portions within 15 minutes. The reaction mixture was cooled to 20-25° C. and after 5 minutes 48.5 g (0.27 mol) HQO and 0.33 g (1 mol %) 4-dimethylaminopyridine were added in one portion. The reaction mixture was heated to 30-35° C. and stirred for 2 hours, then 26.5 ml (0.7 equiv) trifluoroacetic anhydride was added. The reaction mixture was stirred for additional 2 hours, then diluted with 800 ml of 10% sodium carbonate. From the mixture dichloromethane was distilled off. The precipitated solid was filtered, washed with water (3×100 ml) and dried. Yield is 97%.
  • Crude Dolasetron base (84 g) was dissolved in isobutyl acetate (2.6 L) at 95-100° C. Charcoal (4.2 g) was added to the solution, and after 10 minutes of stirring it was filtered off, and washed with isobutyl acetate (0.26 L). The solution was evaporated under reduced pressure to obtain a residue weighing 0.5-0.6 kg, which allowed to cool to room temperature, and then further cooled in a fridge overnight. The precipitated crystals were filtered off, washed with isobutyl acetate (2×50 ml), and dried overnight at 40-45° C. under reduced pressure. Yield was 88%.
  • Example 10 Preparation of DLS-Base Without Catalyst
  • Indole-3-carboxylic acid (17.7 g, 1.1 equiv.) was added in portions to a solution of trifluoroacetic anhydride (20 ml, 1.4 equiv.) in a mixture toluene (360 ml) and trifluoroacetic acid (90 ml), at room temperature (20-25° C.), during 15 minutes. After 5-minutes of stirring, endo-5-hydroxy-8-azatricyclo[5.3.1.03,8]-undecan-10-one (18.12 g, 0.1 mol), was added in one portion. The reaction mixture heated to 30-35° C., the solid phase dissolved. The solution was stirred for 2 hours without external heating. The trifluoroacetic acid was removed by evaporation under reduced pressure until starting of crystallization. 10% of an aqueous solution of sodium carbonate (360 ml) was added, then toluene was removed by evaporation under reduced pressure. The precipitated Dolasetron base monohydrate was collected by filtration, washed with water (3×60 ml), and dried overnight at 40° C. under reduced pressure. The dry product was weighed as 33.63 g (98%).
  • The dried crude Dolasetron base was dissolved in isobutyl acetate (1 L) at 95-100° C. Charcoal (1.7 g) was added to the solution, and after 10 minutes of stirring it was filtered off, and washed with isobutyl acetate (0.1 L). The solution was evaporated under reduced pressure to obtain a residue weighing 0.20-0.25 kg, which allowed to cool to room temperature, and then further cooled in a fridge overnight. The precipitated crystals were filtered off, washed with isobutyl acetate (2×20 ml), and dried overnight at 40-45° C. under reduced pressure. Yield was 88%.
  • Example 11 Preparation of DLS-MsOH of Formula VIII
  • Methanesulfonic acid (2.85 ml, 1 equiv) was added to a stirred suspension of Dolasetron base (14.24 g, 43.9 mmol) in a mixture of acetone-water 95:5 (100 ml). The solid dissolved immediately, after some minutes the salt precipitated in crystalline form. The mixture was put into fridge, after 4 hours the salt was filtered off, washed with same solvent mixture (2×15 ml), dried overnight in an air-ventilated oven at 40° C. The yield was 15.63 g (81%).
  • Example 12 Preparation of SAN from HAN
  • In a 250-ml flask HAN (41 mmol) was dissolved in methylene chloride (120 ml). The solution was mixed with 1.5 equiv (7 g) of imidazole at 20-25° C. After complete dissolution, to this solution 1.3 equiv (12.4 g) of tert-butyldimethylsilyl chloride was added and the reaction mixture was stirred for 6 hours. The conversion was monitored by TLC (eluent:ethyl acetate). The reaction mixture was washed with water (2×40 ml). The combined aqueous layer was washed with methylene chloride (120 ml). The combined organic phase was dried on sodium sulfate, evaporated to dryness on rotavapor at 40-45° C. The product was about 19 g of oil.
  • Example 13 Preparation of SAN from HAN-Mesylate
  • In a 500-ml flask HAN-mesylate (70 mmol) was mixed with methylene chloride (260 ml). To the suspension 4.5 equiv (21 g) of imidazole was added at 20-25° C. After complete dissolution, to this solution 2 equiv (21 g) of tert-butyldimethylsilyl chloride was added and the reaction mixture was stirred for 2 days at 40-45° C. The conversion was monitored by TLC (eluent:ethyl acetate). The reaction mixture was diluted with methylene chloride (260 ml), washed with water (2×130 ml). The combined organic phase was dried on sodium sulfate, evaporated to dryness on rotavapor at 40-45° C. The product is about 32 g of oil.
  • Example 14 Preparation of SQO
  • In a 250-ml flask the crude SAN (ca 19 g, theoretically 41 mmol) was dissolved in THF (190 ml) and potassium tert-butoxide (9.2 g, 2 equiv) was added under stirring. The solution was heated to reflux for 2 hours, and 95 ml of THF was distilled off during this reflux period. The mixture was cooled to 20-25° C. and aqueous acetic acid (5.4 ml/94 mmol/of acetic acid in 80 ml of water) was added, then the pH is adjusted to 7-8 by addition of solid sodium hydrogencarbonate (6-7 g). The rest of THF was distilled off, then the aqueous mixture was cooled to 20-25° C., and stored in the fridge (2-8° C.) overnight. The precipitated material was filtered off, washed with water, and dried in vacuum. The product was 7.5 g of white solid.
  • Example 15 Preparation of HQO from SQO
  • In a 250-ml flask SQO (10.6 g) was suspended in 22 ml of water at 20-25° C. and 3 equiv (4.5 ml) cc HCl was added. The obtained clear solution (pH 1) was stirred for 6 hours at reflux temperature. The conversion was monitored by TLC (eluent: 1:1 methylene chloride-methanol). The reaction mixture was cooled to 20-25° C. and the pH of the solution was adjusted to 12 by addition of solid sodium hydroxide under cooling. The solution was extracted with methylene chloride (5×50 ml). The combined organic phase was dried on sodium sulfate, and evaporated to dryness on rotavapor at 30-35° C. The residue was 4.7 g of white solid.
  • Example 16 Preparation of HQO from SAN
  • In a 250-ml flask the crude SAN (ca 4 g, theoretically 10 mmol) was dissolved in THF (50 ml) and potassium tert-butoxide (1.6 g, 1.4 equiv) was added under stirring. The solution was heated to reflux for 2 hours, and 25 ml of THF was distilled off during this reflux period. The mixture was cooled to 20-25° C., diluted with water (15 ml), and the pH was adjusted to 1 with concentrated HCl. The rest of THF was distilled out, and the mixture was refluxed for 6 hours, then cooled to 20-25° C. The pH of the solution was adjusted to 12 by addition of solid sodium hydroxide under cooling. The basic solution was extracted with methylene chloride (5×30 ml). The combined organic phase was dried on sodium sulfate, and evaporated to dryness. The residue was 0.82 g of brownish solid.

Claims (150)

1. A quaternary ammonium salt of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (an OAN salt) of formula Vs,
Figure US20070203175A1-20070830-C00053
wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, and Z is an acid.
2. (canceled)
3. The quaternary ammonium salt of claim 1, wherein R1 and R2 are methyl and Z is methanesulfonic acid.
4. The quaternary ammonium salt of claim 3, wherein the quaternary ammonium salt is crystalline.
5. The quaternary ammonium salt of claim 4, wherein the quaternary ammonium salt is crystalline OAN-MsOH is characterized by a powder XRD diffraction pattern having peaks at about 8.5, 18.0, and 20.9 degrees two-theta, ±0.2 degrees two-theta.
6. (canceled)
7. The quaternary ammonium salt of claim 6, wherein the crystalline OAN-MsOH is characterized having a PXRD pattern as depicted in FIG. 1.
8. A quaternary ammonium salt of 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-ol (a HAN salt) of formula VIs,
Figure US20070203175A1-20070830-C00054
wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, and Z is an acid.
9. (canceled)
10. The quaternary ammonium salt of claim 8, wherein R1 and R2 are methyl and Z is methanesulfonic acid.
11. The quaternary ammonium salt of claim 10, wherein the quaternary ammonium salt is crystalline.
12. The quaternary ammonium salt of claim 11, wherein the quaternary ammonium salt is crystalline HAN-MsOH characterized by a powder XRD diffraction pattern having peaks at about 7.3, 11.6, and 14.6 degrees two-theta, ±0.2 degrees two-theta.
13. (canceled)
14. (canceled)
15. A 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (a SAN compound) of formula X
Figure US20070203175A1-20070830-C00055
wherein R1 and R2 are independently C1-6 alkyl or C6-8 aryl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or R3R4R5 together are a tert-butyldialkyl.
16. (canceled)
17. The compound of claim 15, wherein R1 and R2 are methyl and R3R4R5 is tert-butyldimethyl.
18. An endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one compound (a SQO compound) of formula XII
Figure US20070203175A1-20070830-C00056
wherein R is a C1-6 alkyl or a C6-8 aryl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or R3R4R5 together are a tert-butyldialkyl.
19. (canceled)
20. The compound of claim 18, wherein R is methyl, and R3R4R5 are together tert-butyldimethyl.
21. The compound of claim 20, wherein the compound is crystalline.
22. The compound of claim 21, wherein the compound is crystalline SQO, characterized by a powder XRD diffraction pattern having peaks at about 5.1, 10.1, 12.7, and 20.3 degrees two-theta, ±0.2 degrees two-theta.
23. (canceled)
24. (canceled)
25. A quaternary ammonium salt of endo-5-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (a HQO salt) of formula IIs,
Figure US20070203175A1-20070830-C00057
wherein Y an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acid.
26. The quaternary ammonium salt of claim 25, wherein Y is Hydrochloric acid (HQO-HCl).
27. The quaternary ammonium salt of claim 26, wherein the salt is crystalline.
28. (canceled)
29. The quaternary ammonium salt of claim 25, wherein Y is Camphorsulfonic acid (HQO—CSA).
30. The quaternary ammonium salt of claim 29, wherein the salt is crystalline.
31. (canceled)
32. A method for the preparation of a CCA-epoxide of formula IV
Figure US20070203175A1-20070830-C00058
comprising combining a CCA-ester of formula III,
Figure US20070203175A1-20070830-C00059
an oxidizing agent, a catalyst, and a solvent selected from the group consisting of water, a water miscible organic solvent, and mixtures thereof forming a mixture, to obtain the CCA-epoxide of formula IV, wherein, R1 is a C1-6 alkyl or C6-8 aryl.
33. The method of claim 32, wherein RI is methyl.
34. The method of claim 32, wherein the oxidizing agent is selected from the group consisting of: hydroxyperoxide, dialkyl peroxide, peroxyacid, peroxyester, diacyl peroxide, persulphate, perborate, and perphosphate.
35. (canceled)
36. The method of claim 34, wherein the hydroperoxide is hydrogen peroxide.
37. The method of claim 32, wherein the water miscible organic solvent is selected from the group consisting of linear or branched C1-4 alcohols.
38. (canceled)
39. The method of claim 32, wherein the solvent is a mixture of water and a water immiscible organic solvent in the presence of a phase transfer catalyst.
40. The method of claim 39, wherein the water immiscible organic solvent is selected from the group consisting of a C1-8 halogenated hydrocarbon, a C2-8 ester, a C2-8 ether and a C3-6 ketone.
41. The method of claim 32, wherein the catalyst is selected from the group consisting of Zeolites and polyoxometalates.
42. The method of claim 41, wherein the metal moiety of the polyoxometalates is selected from the group consisting of tungsten, molybdenum, rhenium, vanadium and niobium.
43. (canceled)
44. (canceled)
45. The method of claim 32, wherein the reaction mixture is maintained at a temperature of about 0° C. to about 80° C.
46. The method of claim 32, further comprising recovering the CCA-epoxide of formula IV.
47. (canceled)
48. (canceled)
49. (canceled)
50. A method for the preparation of a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-one compound (an OAN compound) of formula V
Figure US20070203175A1-20070830-C00060
comprising
a) combining a CCA-epoxide of formula IV, an oxidizing agent, and a solvent selected from the group consisting of water, water miscible organic solvent, and mixtures thereof to form a reaction mixture;
b) raising the pH of the reaction mixture; and
c) reacting the reaction mixture of step b) with a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance containing a carbonyl moiety selected from the group consisting of 1,3-acetonedicarboxylic acids, acetone and C1-4 esters thereof to form an OAN compound of formula V,
wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl.
51. The method of claim 50, wherein R1 and R2 are methyl.
52. The method of claim 50, wherein the water miscible organic solvent is selected from the group consisting of: a C2-4 nitrile, a C3-6 ketone and a cyclic ether.
53. (canceled)
54. The method of claim 50, wherein the solvent is water.
55. The method of claim 50, wherein the oxidizing agent is selected from the group consisting of: periodic acid and salts thereof, lead tetraacetate, cerium and ammonium nitrate (Ce(NH4)2(NO3)6).
56. (canceled)
57. The method of claim 50, wherein the reaction mixture is maintained at a temperature of about 10° C. to about 60° C.
58. The method of claim 57, wherein the pH of the first reaction mixture is of about 0.5 to about 7.
59. (canceled)
60. The method of claim 59, wherein the pH is raised by using a water immiscible base selected from poly(4-vinylpyridine) and OH resins.
61. The method of claim 50, wherein the pH 4 buffer is an amine-free buffer selected from the group consisting of: citric acid-sodium hydroxide-hydrochloric acid, citric acid-disodium hydrogenphosphate, sodium acetate-acetic acid, potassium diphthalate-sodium hydroxide, sodium dihydrogen phosphate and potassium hydrogen phthalate.
62. (canceled)
63. (canceled)
64. (canceled)
65. (canceled)
66. The method of claim 64, wherein the glycine C1-4 ester is glycin methylester hydrochloride.
67. The method of claim 50, wherein the substance comprising a carbonyl moiety is 1,3-acetonedicarboxylic acid.
68. The method of claim 50, wherein the reaction mixture in step c) is maintained at a temperature of about 0° C to about 60° C.
69. (canceled)
70. (canceled)
71. The method of claim 50, further comprising; combining the OAN compound of formula V, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof, forming a mixture to obtain an OAN-salt of formula Vs
Figure US20070203175A1-20070830-C00061
wherein, R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl, and Z is an acid.
72. The method of claim 71, wherein Z is methanesulfonic acid.
73. (canceled)
74. (canceled)
75. (canceled)
76. The method of claim 71, wherein the mixture of the OAN compound of formula V, the solvent and the acid form is maintained at a temperature of about 10° C. to about 60° C.
77. The method of claim 71, further comprising adding a base, wherein the OAN compound of formula V is obtained as a purified compound.
78. (canceled)
79. (canceled)
80. A method of preparing a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonane-3-ol compound (a HAN compound) of formula VI
Figure US20070203175A1-20070830-C00062
comprising combining an OAN salt of formula Vs, a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof to form mixture, to obtain an HAN compound of formula VI, wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl.
81. The method of claim 80, wherein R1 and R2 are methyl.
82. The method of claim 80, wherein the OAN salt is OAN-MsOH.
83. The method of claim 80, wherein the water miscible organic solvent is a C1-4 alcohol.
84. (canceled)
85. The method of claim 80, wherein the reducing reagent is a metal hydride complex.
86. (canceled)
87. The method of claim 80, wherein the mixture comprising the OAN salt, the water miscible organic solvent, and the reducing agent is maintained at a temperature of about 25° C. to about 35° C.
88. The method of claim 80, further comprising recovering the HAN compound of formula VI.
89. (canceled)
90. (canceled)
91. The method of claim 80, further comprising combining the HAN compound of formula VI, an acid, and an organic solvent selected from the group consisting of a C1-4 alcohol, a C2-8 ester, a linear, branched or cyclic C2-8 ether, a C3-6 ketone, a C5-8 aliphatic hydrocarbon, a C1-8 halogenated hydrocarbon, a C1-4 nitroalkane, a C1-4 alkylcyanide, a C6-8 aromatic hydrocarbon, a C3-10 amide, and mixtures thereof, forming a mixture to obtain a HAN-salt of formula VIs
Figure US20070203175A1-20070830-C00063
wherein R1 and R2 are independently a C1-6 alkyl or a C6-8 aryl and Z is an acid.
92. (canceled)
93. The method of claim 91, further comprising adding a base, wherein the HAN compound of formula V is obtained as a purified compound.
94. (canceled)
95. (canceled)
96. (canceled)
97. (canceled)
98. A method of preparing a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (a SAN compound) of formula X
Figure US20070203175A1-20070830-C00064
comprising combining a HAN-salt of formula VIs
Figure US20070203175A1-20070830-C00065
a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent, forming a mixture to obtain the SAN compound of formula X,
wherein, R1 and R2 are independently C1-6 alkyl or C6-8 aryl, and R3R4R5 are independently C1-6 alkyl or C6-8 aryl, or R3R4R5 together are a tert-butyldialkyl, and Z is an acid.
99. The method of claim 98, wherein R1 and R2 are methyl, R3R4R5 together are tert-butyldimethyl.
100. The method of claim 98, wherein the a-protic organic solvent is selected from the group consisting of a C1-8 halogenated hydrocarbon, a C2-8 ester, a C2-8 ether, a C6-8 aromatic hydrocarbon, a C3-10 amide, and a C3-6 ketone.
101. (canceled)
102. The method of claim 98, wherein the amount of base is about 2 to about 10 mole equivalent of base per mole equivalent of the HAN-salt.
103. The method of claim 98, wherein the base is selected from the group consisting of: sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate potassium bicarbonate, trialkyl amines, and N-containing heterocycles.
104. (canceled)
105. (canceled)
106. The method of claim 98, wherein the base is added at a temperature of about 15° C. to about 55° C.
107. The method of claim 98, wherein the silylating agent is selected from the group consisting of triethylsilane, triisopropylsilane, and triphenylsilane.
108. The method of claim 98, wherein the silylating agent is trialkylsilyl halogenide.
109. (canceled)
110. The method of claim 108, wherein the silylating agent is added in an amount of about 1 to about 4 mole equivalent of sylilating agent per mole equivalent of the HAN-salt.
111. The method of claim 98, wherein the mixture is maintained at a temperature of about 20° C. to about 60° C.
112. The method of claim 98, further comprising recovering SAN of formula X.
113. (canceled)
114. (canceled)
115. A method of preparing an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one compound (a SQO compound) of formula XII
Figure US20070203175A1-20070830-C00066
comprising,
a) mixing a SAN compound of formula X, a metal alkoxide, and a polar aprotic organic solvent to form a mixture;
b) heating the mixture; and
c) reacting the heated mixture of step b) with a weak acid, forming-the SQO compound of formula XII,
wherein, R is a C1-6 alkyl or a C6-8 aryl, and R3R4R5 are independently a C1-6 alkyl or a C6-8 aryl, or R3R4R5 together are a tert-butyldialkyl.
116. The method of claim 115, wherein R is methyl and R3R4R5 together are tert-butyldimethyl.
117. (canceled)
118. The method of claim 115, wherein the polar a-protic organic solvent is THF.
119. The method of claim 115, wherein the metal alkoxide is selected from the group consisting of lithium alcoholates, sodium alcoholates and potassium alcoholates; wherein the alcoholate moiety contains 1 to 4 carbons.
120. (canceled)
121. The method of claim 115, wherein the mixture is heated to a temperature of about 40° C. to about 120° C.
122. The method of claim 121, wherein the heated mixture is cooled to a temperature of about 0° C. to about 30° C.
123. The method of claim 115, wherein the weak acid is selected from the group consisting of acetic acid, formic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids
124. The method of claim 123, wherein the acid is acetic acid.
125. (canceled)
126. The method of claim 115, further comprising recovering the SQO compound of formula XII.
127. (canceled)
128. (canceled)
129. A method of preparing endo-5-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (HQO) of formula II
Figure US20070203175A1-20070830-C00067
comprising mixing a SQO compound of formula XII, water or a water-miscible organic solvent, and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids, to obtain the HQO compound.
130. The method of claim 129, wherein the water-miscible organic solvent is dimethylformamide, dimethylacetamide, dimethyl sulfoxide, or diglyme.
131. The method of claim 129, wherein the solvent is water.
132. The method of claim 129, wherein the SQO compound of formula XII is combined with the solvent at a temperature of about 10° C. to about 50° C.
133. (canceled)
134. The method of claim 129, wherein the mixture is heated to a temperature of about 80° C. to about 100° C.
135. The method of claim 129, further comprising recovering HQO of formula II.
136. The method of claim 129, wherein HQO is prepared comprising combining a SAN compound of formula X, in stead of the SQO compound of formula XII.
137. (canceled)
138. The method of claim 129, further comprising combining HQO, an alcohol and an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, salicylic acid, naphthalene carboxylic and dicarboxylic acids, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene sulfonic, and disulfonic acid to obtain a HQO salt of formula IIs.
139. The method of claim 138, further comprising the step of adding a base to obtain purified HQO.
140. The method of claim 138, wherein the alcohol is a C1-4 alcohol.
141. (canceled)
142. (canceled)
143. (canceled)
144. (canceled)
145. (canceled)
146. (canceled)
147. (canceled)
148. (canceled)
149. (canceled)
150. A method of preparing a Dolasetron salt of formula VIIIs, comprising
a) combining a CCA-ester of formula III, an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form CCA-epoxide of formula IV;
b) admixing CCA-epoxide with an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent;
c) raising the pH;
d) admixing with a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3 acetonedicarboxylic acids, acetone and a C1-4 ester thereof, to form OAN of formula V;
e) admixing with a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form HAN of formula VI;
f) admixing with a silylating agent selected from a group consisting of:
silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to form SAN of formula X;
g) admixing with a metal alkoxide, and a polar a-protic organic solvent to form a reaction mixture;
h) heating the reaction mixture;
i) quenching with a weak acid selected from the group consisting of acetic acid, formic acid, acetic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, and salicylic acid forming SQO of formula XII;
j) admixing with a solvent selected from a group consisting of: water, and water-immiscible organic solvent, and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids to form HQO of formula II;
k) admixing with an anhydride, 3-indole carboxylic acid, a halogenated hydrocarbon, and a catalyst to obtain Dolasetron base; and
l) reacting Dolasetron base with an acid to obtain the DLS-salt of formula VIIIs.
US11/650,355 2006-01-05 2007-01-05 Productioin of dolasetron Abandoned US20070203175A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/650,355 US20070203175A1 (en) 2006-01-05 2007-01-05 Productioin of dolasetron

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US75669006P 2006-01-05 2006-01-05
US76368306P 2006-01-30 2006-01-30
US78424806P 2006-03-20 2006-03-20
US80088406P 2006-05-15 2006-05-15
US80284206P 2006-05-22 2006-05-22
US81519906P 2006-06-19 2006-06-19
US81893406P 2006-07-05 2006-07-05
US83351506P 2006-07-24 2006-07-24
US83643206P 2006-08-07 2006-08-07
US83875806P 2006-08-17 2006-08-17
US85288706P 2006-10-18 2006-10-18
US86135406P 2006-11-27 2006-11-27
US11/650,355 US20070203175A1 (en) 2006-01-05 2007-01-05 Productioin of dolasetron

Publications (1)

Publication Number Publication Date
US20070203175A1 true US20070203175A1 (en) 2007-08-30

Family

ID=37913602

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/650,294 Expired - Fee Related US7608714B2 (en) 2006-01-05 2007-01-05 Production of dolasetron
US11/650,349 Abandoned US20070203176A1 (en) 2006-01-05 2007-01-05 Crystalline forms of dolasetron base and processes for preparation thereof
US11/650,355 Abandoned US20070203175A1 (en) 2006-01-05 2007-01-05 Productioin of dolasetron
US11/650,352 Abandoned US20070203177A1 (en) 2006-01-05 2007-01-05 Forms of dolasetron mesylate and processes for their preparation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/650,294 Expired - Fee Related US7608714B2 (en) 2006-01-05 2007-01-05 Production of dolasetron
US11/650,349 Abandoned US20070203176A1 (en) 2006-01-05 2007-01-05 Crystalline forms of dolasetron base and processes for preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/650,352 Abandoned US20070203177A1 (en) 2006-01-05 2007-01-05 Forms of dolasetron mesylate and processes for their preparation

Country Status (5)

Country Link
US (4) US7608714B2 (en)
EP (4) EP1861397A2 (en)
IL (4) IL190725A0 (en)
TW (2) TW200734326A (en)
WO (4) WO2007081907A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062546A1 (en) * 2007-07-20 2009-03-05 Janos Hajko Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof
US20090030207A1 (en) * 2007-07-20 2009-01-29 Janos Hajko Polymorphs of Dolasetron base and process for preparation thereof
ES2389261T3 (en) * 2007-11-13 2012-10-24 Inke, S.A. Intermediate compounds useful for preparing dolasetron
US8969262B2 (en) * 2008-06-04 2015-03-03 Nalco Company Utilization of an anhydride as a demulsifier and a solvent for demulsifier formulations
US9096805B2 (en) * 2008-06-04 2015-08-04 Nalco Company Anhydride demulsifier formulations for resolving emulsions of water and oil
CN102180878B (en) * 2010-07-02 2013-06-26 成都新恒创药业有限公司 Dolasetron isomer or salt thereof, preparation method for the Dolasetron isomer or salt thereof and application of the Dolasetron isomer or salt thereof
CN103360392A (en) * 2013-06-21 2013-10-23 辽宁海思科制药有限公司 Dolasetron mesylate compound
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2018097150A1 (en) * 2016-11-24 2018-05-31 帝人ファーマ株式会社 Epoxy compound production method
CN109503580A (en) * 2019-01-15 2019-03-22 南京恩泰医药科技有限公司 A kind of dolasetron mesilate crystal form and preparation method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878096B (en) 1986-11-03 1988-04-26 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
EP0329905A1 (en) 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility
EP0330788A1 (en) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
ZA893008B (en) 1988-04-29 1989-12-27 Merrell Dow Pharma Process for preparing indole-3-carboxylic acid esters of transhexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines
US5665890A (en) * 1995-03-14 1997-09-09 President And Fellows Of Harvard College Stereoselective ring opening reactions
CN100390172C (en) * 2004-09-10 2008-05-28 成都欣捷高新技术开发有限公司 A kind of crystal form of dolasetron mesylate and preparation method thereof
US20070299260A1 (en) * 2004-11-25 2007-12-27 Cilag Ltd. Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters
ES2314927T3 (en) 2005-07-06 2009-03-16 Inke, S.A. PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND, ITS SYNTHESIS INTERMEDIATES AND PROCEDURES FOR OBTAINING THEMSELVES.
WO2007072506A2 (en) 2005-12-23 2007-06-28 Usv Limited Polymorphic forms of dolasetron mesylate and processes thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds

Also Published As

Publication number Publication date
EP1874767A2 (en) 2008-01-09
IL190723A0 (en) 2008-11-03
EP1861397A2 (en) 2007-12-05
US20070203177A1 (en) 2007-08-30
WO2007081889A8 (en) 2008-08-21
TW200734326A (en) 2007-09-16
US20070203219A1 (en) 2007-08-30
WO2007081890A2 (en) 2007-07-19
US20070203176A1 (en) 2007-08-30
TW200734339A (en) 2007-09-16
IL190724A0 (en) 2008-11-03
WO2007081909A2 (en) 2007-07-19
EP1968978A2 (en) 2008-09-17
IL190914A0 (en) 2008-11-03
WO2007081907A2 (en) 2007-07-19
WO2007081907A3 (en) 2008-01-17
WO2007081890A3 (en) 2007-09-27
IL190725A0 (en) 2008-11-03
US7608714B2 (en) 2009-10-27
EP1968588A2 (en) 2008-09-17
WO2007081889A2 (en) 2007-07-19
WO2007081889A3 (en) 2007-08-23
WO2007081890A8 (en) 2008-08-14
WO2007081889A9 (en) 2007-09-20
WO2007081909A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EP2262804B1 (en) Polysubstituted derivatives of 6-heteroaryl-imidazo[l,2- a] pyridines, and preparation and therapeutic use thereof
EP2262805B1 (en) Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[l,2-a] pyridines, and preparation and therapeutic use thereof
US20070203175A1 (en) Productioin of dolasetron
US6552186B2 (en) β-lactam production
US7982051B2 (en) Methods for preparing diazonamides
WO2013135165A1 (en) Synthetic intermediate of entecavir and method for preparing same
US11008296B2 (en) Intermediates for the preparation of eribulin thereof
JP6388065B2 (en) Method for producing difluoroester compound
US9434740B2 (en) Taxane compounds, compositions and methods
JP5496908B2 (en) Intermediates and methods for making zeralenone macrolide analogs
US20230357137A1 (en) Synthesis of Sulfonamide Intermediates
US7030243B1 (en) Process for making camptothecin derivatives
JP4126555B2 (en) Optically active dioxycyclohexane compound and method for producing optically active hydroxyethylenedioxycyclohexane compound
US9284327B2 (en) Taxane compounds, compositions and methods
US20080207936A1 (en) Method of Producing 3-Hydroxybutyraldehyde Derivative
US20190047939A1 (en) Process and intermediates for the production of 17(20)-ene b-seco steroids
WO2012077456A1 (en) Production method for ether, ester, and thioether
WO2010095617A1 (en) Process for producing 4-chloroazetidinone compound
CA2092091A1 (en) Epoxycarbacyclin precursors, their preparation and their use
HK1119160B (en) Methods for making 3-o protected morphinones and 3-o-protected morphinone dienol carboxylates

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA, GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAJKO, JANOS;TAMAS, TIVADAR;KOVACSNE-MEZEI, ADRIENNE;AND OTHERS;REEL/FRAME:019259/0706;SIGNING DATES FROM 20070219 TO 20070221

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF RIGHTS IN BARBADOS;ASSIGNOR:TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG;REEL/FRAME:019259/0329

Effective date: 20070226

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION